Substituted benzamides as RIPK2 inhibitors

ABSTRACT

The present invention relates to compounds of formula (I): 
                         
or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

BACKGROUND OF THE INVENTION

1. Technical Field

The present invention relates to a series of novel heteroarylcarboxamide compounds, the synthesis of these compounds their use in thetreatment of inflammatory disease and pharmaceutical compositionscomprising these compounds

2. Background Information

RIPK2 (also known as RICK, CARDIAK, CARD3, or RIP2) is a dual specificserine/threonine and tyrosine kinase which is a key component ofpro-inflammatory signaling through the NOD1 and NOD2 signaling pathways(Inohara et al. 1998; McCarthy et al. 1998; Thome et al. 1998;Tigno-Aranjuez et al. 2010). The NOD receptors are one of the mechanismsfor surveillance for intracellular bacterial pathogens. Bacterial cellwall components initiate signals through the NOD1 and NOD2 pathway bythe binding of NOD1 bacteria ligands, D-glutamyl-meso-diaminopimelicacid, and the NOD2 ligand, muramyl dipeptide, to the appropriateintracellular NOD receptors (Girardin et al. 2003a; Girardin et al.2003b; Girardin et al. 2003c; Chamaillard et al. 2003; Inohara et al.2003). This binding induces oligomerization of the NOD protein throughhomotypic CARD/CARD domain interactions (Inohara et al. 2000; Ogura etal. 2001). This activation of NOD receptors leads to Lys63-linkedpolyubiquitination of RIPK2 through activation of ubiquitin E3 ligasessuch as XIAP, cIAP1, cIAP2, TRAF2, TRAF5, and TRAF6 (Krieg et al. 2009;Bertrand et al. 2009; Yang et al. 2007; Hasegawa et al. 2008) andrecruits the linear ubiquitin system (LUBAC) (Damgaard et al. 2012; VerHeul et al. 2013). Additionally, RIPK2 undergoes autophosphorylation ofTyrosine474 as part of its activation and assembly into the NODsignaling complex (Tigno-Aranjuez et al. 2010). Further RIPK2, dependentassembly of the signaling complex results in the activation of IKKα/β/γand TAK1, leading to activation of NF-κB and MAPK pathways resulting inthe production of proinflammatory cytokines (Yang et al. 2007).

Mutations in NOD2 have been linked to multiple diseases. Activatingmutations have been linked to Early Onset Sarcoidosis (Kanazawa et al.,2005) and Blau syndrome (Miceli-Richard et al., 2001) which affect skin,joints, and eyes. These activating mutations result in increased basalNF-κB activity (Kanazawa et al., 2005). Loss-of-function mutations inthe NOD2 LRR are linked to Crohn's Disease (Ogura et al. 2001; Hugot etal. 2001; Hampe et al. 2001; Hampe 2002; Lesange 2002). In addition,polymorphisms in NOD1 have been linked to atopy (Weidinger et al. 2005)and asthma (Hysi et al. 2005). Additional studies in cellular and invivo mouse models have suggested a role for NOD1 and NOD2 signaling in avariety of diseases such as Graft vs. Host Disease, Arthritis, MultipleSclerosis, and Diabetic Nephropathy (Peaneck et al. 2009; Saha et al.2009; Vieira et al. 2012; Rosenzweig et al. 2010; Joosten et al. 2008;Shaw et al. 2011; Du et al. 2013). Small molecule inhibitors of RIP2kinase (RIPK2) are disclosed in US2013/0023532 A1 but appear to havelimited potency.

Pharmacological inhibition of RIPK2 by a potent and selective smallmolecule inhibitor will attenuate pro-inflammatory signaling through thebacterial sensing pathways initiated by NOD1 and NOD2 stimulation. Thisreduction in inflammatory signaling will provide therapeutic benefit ina variety of autoinflammatory diseases. Thus, there is a need for potentinhibitors of RIPK2 for pharmaceutical purposes.

BRIEF SUMMARY OF THE INVENTION

The present invention provides novel heteroaryl carboxamide series ofcompounds which inhibit the receptor-interacting serine/threonineprotein kinase 2 (RIPK2) and are thus useful for treating a variety ofdiseases and disorders that are mediated or sustained through theactivity of RIPK2 including inflammatory, cardiometabolic andcardiovascular diseases and cancer. This invention also relates topharmaceutical compositions comprising these compounds, methods of usingthese compounds in the treatment of various diseases and disorders,processes for preparing these compounds and intermediates useful inthese processes.

In one aspect of the invention, a compound of this invention has goodbinding potency.

In another aspect of the invention, a compound this invention exhibitsgood cellular potency.

In yet another aspect, a compound of this invention exhibits goodstability.

In another aspect, a compound of this invention exhibits good cellpermeability.

DETAILED DESCRIPTION OF THE INVENTION

In its broadest embodiment, the present invention relates compounds offormula I:

or pharmaceutically acceptable salts thereof, wherein:

X is N and Y is CH; or

X is CH and Y is N;

HET is a 5-membered heteroaryl ring containing one to three heteroatomsselected from nitrogen and sulfur, wherein each heteroaryl ring isoptionally substituted with one to two substituents groups independentlyselected from R³ and R⁴; or

HET is a 5-membered heteroaryl ring containing one to three heteroatomsselected from nitrogen and sulfur, wherein each heteroaryl ring issubstituted with two substituents groups selected from R^(a) and R^(b),wherein R^(a) and R^(b) together with the atoms to which they areattached form a 5-6 membered heterocyclic or heteroaryl ring which maybe optionally substituted with one to two substituents selected from R³and R⁴;

R¹ is hydrogen or F;

R² is C₁₋₃ alkyl or Cl;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —O R⁵,    -   (c) —O— C₁₋₆alkyl-O— C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)_(n)—R⁵,    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)_(n)C₁₋₆alkyl,    -   (m) 4-10 membered monocyclic, bicyclic or spirocyclic        heterocyclyl group containing N, S or O, wherein each        heterocycle is optionally substituted with 1-3 substituents        selected from 3-6 membered heterocyclic ring, halogen,        —C₁₋₃alkyl, —C₁₋₃alkyl —O—C₁₋₃alkyl and        —C₁₋₃alkyl-C(O)N(R⁵)(R⁶),    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl,wherein each R⁵ and R⁶ is independently optionally substituted with —OH,C₃₋₆ cycloalkyl, —C₁₋₃alkyl, —O—C₁₋₃alkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 4-6 membered heterocyclic ring optionally substituted withmethyl; and

n is 0, 1, or 2.

In a second embodiment, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

X is N and Y is CH; or

X is CH and Y is N;

Het is a 5-membered heteroaryl ring selected from pyrazolyl, imidazolyl,thiazolyl and thiadiazolyl, wherein each heteroaryl ring is optionallysubstituted with one to two substituents groups independently selectedfrom R³ and R⁴; or

Het is a 5-membered heteroaryl ring selected from pyrazolyl andimidazolyl, wherein each heteroaryl ring is substituted with twosubstituents groups selected from R^(a) and R^(b), wherein R^(a) andR^(b) together with the atoms to which they are attached form a 5-6membered heterocyclic or heteroaryl ring which may be optionallysubstituted with one to two substituents selected from R³ and R⁴;

R¹ is hydrogen or F;

R² is C₁₋₃ alkyl or Cl;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —O R⁵,    -   (c) —O—C₁₋₆alkyl-O—C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O—C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)_(n)—R⁵    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)_(n)C₁₋₆alkyl,    -   (m) 4-10 membered monocyclic, bicyclic or spirocyclic        heterocyclyl group containing N, S or O, wherein each        heterocycle is optionally substituted with 1-3 substituents        selected from 3-6 membered heterocyclic ring, halogen,        C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶).    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyloptionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 5-6 membered heterocyclic ring optionally substituted withmethyl; and

n is 0 or 2.

In a third embodiment, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

X is N and Y is CH.

In a fourth embodiment, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

X is CH and Y is N.

In a fifth embodiment, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is a 5-membered heteroaryl ring selected from pyrazolyl, imidazolyl,thiazolyl and thiadiazolyl, wherein each heteroaryl ring is optionallysubstituted with one to two substituents groups independently selectedfrom R³ and R⁴;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —O R⁵,    -   (c) —O—C₁₋₆alkyl-O—C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O—C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)—R⁵    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)_(n)C₁₋₆alkyl,    -   (m) 4-10 membered monocyclic, bicyclic or spirocyclic        heterocyclyl group containing N, S or O, wherein each        heterocycle is optionally substituted with 1-3 substituents        selected from 3-6 membered heterocyclic ring, halogen,        C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶).    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyloptionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 5-6 membered heterocyclic ring optionally substituted withmethyl; and

n is 0 or 2.

In a sixth embodiment, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is a 5-membered heteroaryl ring selected from pyrazolyl andimidazolyl, wherein each heteroaryl ring is substituted with twosubstituents groups selected from R^(a) and R^(b); wherein

R^(a) and R^(b) together with the atoms to which they are attached forma 5-6 membered heterocyclic or heteroaryl ring which may be optionallysubstituted with one to two substituents selected from R³ and R⁴;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —O R⁵,    -   (c) —O—C₁₋₆alkyl-O—C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O—C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)_(n)—R⁵    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)_(n)C₁₋₆alkyl,    -   (m) 4-10 membered monocyclic, bicyclic or spirocyclic        heterocyclyl group containing N, S or O, wherein each        heterocycle is optionally substituted with 1-3 substituents        selected from 3-6 membered heterocyclic ring, halogen,        C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶).    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyloptionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 6 membered heterocyclic ring optionally substituted with methyl;and

n is 0 or 2.

In a seventh embodiment, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is pyrazolyl optionally substituted with one to two substituentsgroups selected from R³ and R⁴.

In embodiment eight, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is a 5-membered heteroaryl ring selected from pyrazolyl andimidazolyl, wherein each heteroaryl ring is substituted with twosubstituents groups selected from R^(a) and R^(b); wherein

R^(a) and R^(b) together with the atoms to which they are attached forma 5-6 membered heteroaryl ring such that HET is a bicyclic heteroarylring selected from imidazopyridine and pyrazolopyridine which may beoptionally substituted one to two substituents selected from R³ and R⁴.

In embodiment nine, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

X is N;

Y is CH;

R¹ is F;

R² is selected from methyl and Cl;

HET is selected from imidazopyridine and pyrazolopyridine which may beoptionally substituted with one to two substituents selected from R³ andR⁴;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —O R⁵,    -   (c) —O—C₁₋₆alkyl-O—C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O—C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)₂—R⁵    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂) CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)₂C₁₋₆alkyl,    -   (m) 4-10 membered monocyclic, bicyclic or spirocyclic        heterocyclyl group containing N, S or O, wherein each        heterocycle is optionally substituted with 1-3 substituents        selected from 3-6 membered heterocyclic ring, halogen,        C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶).    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyloptionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 6 membered heterocyclic ring optionally substituted with methyl.

In embodiment ten, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

X is N;

Y is CH;

R¹ is F;

R² is selected from methyl and Cl;

HET is imidazopyridine which may be optionally substituted with one totwo substituents selected from R³ and R⁴;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —OR⁵,    -   (c) —O—C₁₋₆alkyl-O—C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O—C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)₂—R⁵    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂) CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)₂C₁₋₆alkyl,    -   (m) 6 membered monocyclic heterocyclyl group containing N        wherein the heterocycle is optionally substituted with 1-3        substituents selected from 3-6 membered heterocyclic ring,        halogen, C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶).    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyloptionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 6 membered heterocyclic ring optionally substituted with methyl.

In embodiment eleven, the present invention relates to a compound asdescribed in the ninth embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is:

optionally substituted one to two substituents selected from R³ and R⁴;

R³ and R⁴ are each independently selected from:

-   -   (a) —H,    -   (b) —OR⁵,    -   (c) —O—C₁₋₆alkyl-O—C₁₋₃ alkyl    -   (d) —O—C₃₋₆ cycloalkyl,    -   (e) —C(O)R⁵,    -   (f) C₁₋₆alkyl optionally substituted with one to three —OH,        fluorine, heterocyclyl optionally substituted with oxo, C₃₋₆        cycloalkyl, —CO₂R⁵, —O—C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or        —C(O)N(R⁵)(R⁶),    -   (g) C₃₋₆ cycloalkyl optionally substituted with one to three        —OH, one to three fluorine, C₁₋₆alkyl, —OC₁₋₆alkyl,        C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,        —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆        heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),    -   (h) —CO₂R⁵,    -   (i) —C(O)N(R⁵)(R⁶),    -   (j) —S(O)₂N(R⁵)(R⁶),    -   (k) —S(O)₂—R⁵    -   (l) a 5-6 membered heteroaryl group optionally substituted with        one to three groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,        halogen, —CF₃, —OH, —(CH₂) CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶),        —NH—SO₂C₁₋₆alkyl, C₁₋₆alkoxyl, C₁₋₆alkyl-O—C₁₋₃ alkyl,        C₁₋₆alkylhydroxyl, C₁₋₃alkyl-CN, oxo, phenyl optionally        substituted with halogen and —S(O)₂C₁₋₆alkyl,    -   (m) 4-10 membered monocyclic, bicyclic or spirocyclic        heterocyclyl group containing N, S or O, wherein each        heterocycle is optionally substituted with 1-3 substituents        selected from 3-6 membered heterocyclic ring, halogen,        C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶).    -   (n) aryl,    -   (o) —N(R⁵)(R⁶);

R⁵ and R⁶ are each independently selected from —H, 4-6 memberedheterocyclyl, —C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyloptionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or

R⁵ and R⁶ together with the nitrogen atom to which they are attachedform a 6 membered heterocyclic ring optionally substituted with methyl.

In embodiment twelve, the present invention relates to a compound asdescribed in the ninth embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

optionally substituted one to two substituents selected from R³ and R⁴.

In embodiment thirteen, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is:

optionally substituted one to two substituents selected from R³ and R⁴.

In embodiment fourteen, the present invention relates to a compound asdescribed in the broadest embodiment above, or a pharmaceuticallyacceptable salt thereof, wherein:

HET is:

optionally substituted one to two substituents selected from R³ and R⁴.

In embodiment fifteen, the present invention relates to a compound asdescribed in the broadest embodiment, or a pharmaceutically acceptablesalt thereof, wherein:

HET is selected from:

optionally substituted one to two substituents selected from R³ and R⁴.

In embodiment sixteen, the present invention relates to a compound offormula I or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Y is CH;

R¹ is F;

R² is methyl;

HET is:

R³ is methoxy; and

R⁴ is

TABLE 1 The following are representative compounds of the inventionwhich can be made by the general synthetic schemes, the examples, andknown methods in the art. Example Structure Structure Name 1

3-{4-[5-(cyclopropylcarbamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}-7-methoxy-N,N-dimethylimidazo[1,2-a]pyridine-6- carboxamide 2

methyl 3-{4-[5-(cyclopropylcarbamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}imidazo[1,2-a]pyridine-6-carboxylate 3

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-imidazol-1-yl}-N-methylimidazo[1,2-a]pyridine-6- carboxamide 5

4-chloro-N-cyclopropyl-2-fluoro-5-(1-{imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol- 4-yl)benzamide 6

4-chloro-N-cyclopropyl-2-fluoro-5-(1-{imidazo[1,2-a]pyrazin-3-yl}-1H-pyrazol- 4-yl)benzamide 7

4-chloro-N-cyclopropyl-5-[1-(2-acetamido-1,3-thiazol-5-yl)-1H-pyrazol-4-yl]-2- fluorobenzamide 8

5-(1-{8-aminoimidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-chloro-N-cyclopropyl- 2-fluorobenzamide 9

4-chloro-N-cyclopropyl-2-fluoro-5-(1-{6-methoxyimidazo[1,2-a]pyrazin-3-yl}-1H- pyrazol-4-yl)benzamide 10

4-chloro-N-cyclopropyl-2-fluoro-5-{1-[6-(2-methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}benzamide 11

4-chloro-N-cyclopropyl-2-fluoro-5-(1-{pyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazol- 4-yl)benzamide 12

4-chloro-N-cyclopropyl-2-fluoro-5-(1-{imidazo[1,2-a]pyrazin-6-yl}-1H-pyrazol- 4-yl)benzamide 13

N-cyclopropyl-3-(1-{imidazo[1,2-a]pyrazin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 14

N-cyclopropyl-3-[1-(2-acetamido-1,3- thiazol-5-yl)-1H-pyrazol-4-yl]-4-methylbenzamide 15

N-cyclopropyl-3-(1-{imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 16

N-cyclopropyl-3-(1-{imidazo[1,2-a]pyridin-3-yl}-1H-imidazol-4-yl)-4-methylbenzamide 17

N-cyclopropyl-3-[1-(2-acetamido-1,3-thiazol-5-yl)-1H-imidazol-4-yl]-4-methylbenzamide 19

N-cyclopropyl-4-methyl-3-{1-[6-(2- methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}benzamide 20

N-cyclopropyl-4-methyl-3-{1-[6-(2- methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-2-yl]-1H-pyrazol-4-yl}benzamide 21

4-chloro-N-cyclopropyl-2-fluoro-5-(1-{6-methanesulfonylimidazo[1,2-a]pyridin-3- yl}-1H-pyrazol-4-yl)benzamide 22

N-cyclopropyl-4-methyl-3-{1-[6-(2- methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-imidazol-4-yl} benzamide 23

N-cyclopropyl-4-methyl-3-{1-[6-(oxetan-3-ylsulfanyl)imidazo[1,2-a]pyridin-3-yl]- 1H-pyrazol-4-yl}benzamide 25

5-{4-[2-chloro-5-(cyclopropylcarbamoyl)-4-fluorophenyl]-1H-pyrazol-1-yl}-1,3- thiazole-2-carboxamide 26

5-{4-[2-chloro-5-(cyclopropylcarbamoyl)-4-fluorophenyl]-1H-pyrazol-1-yl}-N-methyl- 1,3-thiazole-2-carboxamide 27

N-cyclopropyl-3-{1-[6-(ethanesulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol- 4-yl}-4-methylbenzamide 28

N-cyclopropyl-3-{1-[7-methoxy-6-(2-methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-2-yl]-1H-pyrazol-4-yl}-4- methylbenzamide 29

N-cyclopropyl-4-methyl-3-{1-[5-(2-methylpropane-2-sulfonyl)pyrazolo[1,5-a]pyridin-3-yl]-1H-pyrazol-4-yl}benzamide 30

N-cyclopropyl-3-{1-[6-(ethanesulfonyl)-7-methoxyimidazo[1,2-a]pyridin-2-yl]-1H- pyrazol-4-yl}-4-methylbenzamide31

N-cyclopropyl-3-(1-{7-ethoxyimidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4- methylbenzamide 32

N-cyclopropyl-2-fluoro-5-(1-{imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4- methylbenzamide 33

N-cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(2-methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl} benzamide 34

N-cyclopropyl-2-fluoro-5-(1-{6- methoxyimidazo[1,2-a]pyrazin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 35

N-cyclopropyl-3-{1-[7-methoxy-6-(2-methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4- methylbenzamide 36

N-cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(morpholine-4-sulfonyl)imidazo[1,2- a]pyridin-3-yl]-1H-pyrazol-4-yl}benzamide 37

N-cyclopropyl-4-methyl-3-{1-[6- (morpholine-4-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H- pyrazol-4-yl}benzamide 38

N-cyclopropyl-4-methyl-3-(1-{6-[(4-methylpiperazin-1-yl)sulfonyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl) benzamide 39

N-cyclopropyl-2-fluoro-4-methyl-5-(1-{6-[(4-methylpiperazin-1-yl)sulfonyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl) benzamide 40

methyl 3-{4-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-1H-imidazol-1-yl}imidazo [1,2-a]pyridine-6-carboxylate 41

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-imidazol-1-yl}-N,N-dimethylimidazo[1,2-a]pyridine-6- carboxamide 42

3-[1-(1-tert-butyl-1H-pyrazol-4-yl)-1H- pyrazol-4-yl]-N-cyclopropyl-4-methylbenzamide 43

N-cyclopropyl-4-methyl-3-[1-(1,3-thiazol-5-yl)-1H-pyrazol-4-yl]benzamide 44

3-[1-(2-cyclobutoxy-1,3-thiazol-5-yl)- 1H-pyrazol-4-yl]-N-cyclopropyl-4-methylbenzamide 45

3-[1-(2-cyclopropaneamido-1,3-thiazol-5-yl)-1H-pyrazol-4-yl]-N-cyclopropyl-4- methylbenzamide 46

N-cyclopropyl-4-methyl-3-{1-[2- (morpholin-4-yl)-1,3-thiazol-5-yl]-1H-pyrazol-4-yl}benzamide 47

N-cyclopropyl-4-methyl-3-[1-(2-phenyl-1,3-thiazol-5-yl)-1H-pyrazol-4-yl] benzamide 48

N-cyclopropyl-4-methyl-3-{1-[2-(2-oxo-1,2-dihydropyridin-1-yl)-1,3-thiazol-5- yl]-1H-pyrazol-4-yl}benzamide 49

N-cyclopropyl-4-methyl-3-{1-[2- (pyrrolidin-1-yl)-1,3-thiazol-5-yl]-1H-pyrazol-4-yl}benzamide 50

N-cyclopropyl-4-methyl-3-{1-[2-(piperidin-1-yl)-1,3-thiazol-5-yl]-1H-pyrazol-4- yl}benzamide 53

N-cyclopropyl-3-{1-[2-(hydroxymethyl)-1-methyl-1H-imidazol-5-yl]-1H-pyrazol-4- yl}-4-methylbenzamide 54

N-cyclopropyl-4-methyl-3-[1-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrazol-4-yl] benzamide 55

N-cyclopropyl-3-[1-(1,2-dimethyl-1H- imidazol-5-yl)-1H-pyrazol-4-yl]-4-methylbenzamide 56

3-{4-[5-(cyclopropylcarbamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}imidazo [1,2-a]pyridine-6-carboxylic acid57

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}imidazo[1,2-a]pyridine-6-carboxylic acid 58

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-imidazol-1-yl}imidazo[1,2-a]pyridine-6-carboxylic acid 59

3-{4-[5-(cyclopropylcarbamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}-N-(2-hydroxyethyl)imidazo[1,2-a]pyridine-6- carboxamide 60

3-{4-[5-(cyclopropylcarbamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}-N-[2-(methylamino)ethyl]imidazo[1,2-a]pyridine- 6-carboxamide 61

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}-N-(2-hydroxyethyl)imidazo[1,2-a]pyridine-7- carboxamide 62

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}imidazo[1,2-a]pyridine-7-carboxamide 63

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}-N-[2-(methylamino)ethyl]imidazo[1,2-a] pyridine-7-carboxamide 64

N-cyclopropyl-4-methyl-3-{1-[6- (morpholine-4-carbonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4- yl}benzamide 65

N-cyclopropyl-4-methyl-3-{1-[6-(4- methylpiperazine-1-carbonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl} benzamide 66

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}-N,N-dimethylimidazo[1,2-a]pyridine- 6-carboxamide 67

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}-N-methylimidazo[1,2-a]pyridine-6- carboxamide 68

3-{4-[5-(cyclopropylcarbamoyl)-2- methylphenyl]-1H-pyrazol-1-yl}-N-methylimidazo[1,2-a]pyridine-7- carboxamide 69

3-{4-[5-(cyclopropylcarbamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}-N,N- dimethylimidazo[1,2-a]pyridine-6-carboxamide 70

N-cyclopropyl-2-fluoro-4-methyl-5-{1- [6-(4-methylpiperazine-1-carbonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol- 4-yl}benzamide 71

N-cyclopropyl-2-fluoro-5-{1-[6-(1- hydroxyethyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl- benzamide 72

N-cyclopropyl-3-{1-[6-(1- hydroxyethyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4- methylbenzamide 73

N-cyclopropyl-3-(1-{6-[hydroxy(oxan-4-yl)methyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 74

N-cyclopropyl-3-{1-[6-(1- hydroxyethyl)imidazo[1,2-a]pyridin-3-yl]-1H-imidazol-4-yl}-4-methyl- benzamide 75

N-cyclopropyl-2-fluoro-5-{1-[6-(2- hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4- methylbenzamide 76

3-(1-{6-acetylimidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-N-cyclopropyl- 4-methylbenzamide 77

N-cyclopropyl-4-methyl-3-{1-[6- (oxetane-3-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl} benzamide 78

N-cyclopropyl-3-{1-[7-hydroxy-6-(2- methylpropane-2-sulfonyl)imidazo[1,2-a]pyridin-2-yl]-1H-pyrazol-4- yl}-4-methylbenzamide 79

3-{1-[6-(azetidine-3-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}- N-cyclopropyl-4-methylbenzamide80

N-cyclopropyl-4-methyl-3-{1-[6- (piperidine-4-sulfonyl)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}benzamide 81-1

N-cyclopropyl-2-fluoro-5-(1-{6-[(1R)-1-hydroxyethyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 81-2

N-cyclopropyl-2-fluoro-5-(1-{6-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 82-1

N-cyclopropyl-3-(1-{6-[(1R)-1- hydroxyethyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 82-2

N-cyclopropyl-3-(1-{6-[(1S)-1- hydroxyethyl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 84

N-cyclopropyl-4-methyl-3-[1-(1-methyl- 1H-pyrazol-4-yl)-1H-pyrazol-4-yl]benzamide 85

N-cyclopropyl-3-{1-[7-(2- methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4- methylbenzamide 86

N-cyclopropyl-3-(1-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4- methylbenzamide 87

N-cyclopropyl-3-(1-{5H,6H,7H,8H- imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methylbenzamide 88

N-cyclopropyl-4-methyl-3-{1-[2-(1H- pyrazol-1-yl)-1,3-thiazol-5-yl]-1H-pyrazol-4-yl}benzamide 89

N-cyclopropyl-3-{1-[2-(hydroxymethyl)-1,3-thiazol-4-yl]-1H-pyrazol-4-yl}-4- methylbenzamide 90

N-cyclopropyl-4-methyl-3-{1-[5-(2-methylpropane-2-sulfonyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-3-yl]-1H-pyrazol- 4-yl}benzamide 91

N-cyclopropyl-3-(1-{6-methoxyimidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4- methylbenzamide 92

N-cyclopropyl-2-fluoro-4-methyl-5-(1-{6-[1-(oxetan-3-yl)piperidin-4-yl]imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl) benzamide 93

N-cyclopropyl-5-[1-(6-{1- [(dimethylcarbamoyl)methyl]piperidin-4-yl}imidazo[1,2-a]pyridin-3-yl)-1H- pyrazol-4-yl]-2-fluoro-4-methylbenzamide 94

N-cyclopropyl-2-fluoro-5-[1-(6-{4- fluoro-1-methylpiperidin-4-yl}-7-methoxyimidazo[1,2-a]pyridin-3-yl)- 1H-pyrazol-4-yl]-4-methylbenzamide95

N-Cyclopropyl-5-[1-(6-dimethylamino-methyl-7-methoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-2-fluoro-4-methyl- benzamide 96

N-Cyclopropyl-5-{1-[7-ethoxy-6-(4- fluoro-1-methyl-piperidin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-2-fluoro-4-methyl-benzamide 97

N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(1-methyl-azetidin-3-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}- benzamide 98

N-Cyclopropyl-2-fluoro-4-methyl-5- {1-[6-((R)-1-methyl-pyrrolidin-3-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol- 4-yl}-benzamide 99

N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-((S)-1-methyl-pyrrolidin-3-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}- benzamide 100

N-Cyclopropyl-2-fluoro-5-{1-[6-(4- fluoro-1-methyl-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridin-3-yl]-1H-imidazol-4-yl}-4-methyl-benzamide 101

N-Cyclopropyl-5-{1-[6-(1-ethyl-4- fluoro-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridin-3-yl]-1H- pyrazol-4-yl}-2-fluoro-4-methyl-benzamideor the pharmaceutically acceptable salts thereof.

In one embodiment, the invention relates to any of the compoundsdepicted in Table 1 above and the pharmaceutically acceptable saltsthereof.

For all compounds disclosed hereinabove in this application, in theevent the nomenclature is in conflict with the structure, it shall beunderstood that the compound is defined by the structure. For compoundswith stereogenic centers, the structures show the absolutestereochemistry.

The invention also relates to pharmaceutical preparations, containing asactive substance one or more compounds of the invention, or thepharmaceutically acceptable derivatives thereof, optionally combinedwith conventional excipients and/or carriers.

Compounds of the invention also include their isotopically-labelledforms. An isotopically-labelled form of an active agent of a combinationof the present invention is identical to said active agent but for thefact that one or more atoms of said active agent have been replaced byan atom or atoms having an atomic mass or mass number different from theatomic mass or mass number of said atom which is usually found innature. Examples of isotopes which are readily available commerciallyand which can be incorporated into an active agent of a combination ofthe present invention in accordance with well established procedures,include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous,fluorine and chlorine, e.g., ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P,S, ¹⁸F, and ³⁶Cl, respectively. An active agent of a combination of thepresent invention, a prodrug thereof, or a pharmaceutically acceptablesalt of either which contains one or more of the above-mentionedisotopes and/or other isotopes of other atoms is contemplated to bewithin the scope of the present invention.

The invention includes the use of any compounds of described abovecontaining one or more asymmetric carbon atoms may occur as racematesand racemic mixtures, single enantiomers, diastereomeric mixtures andindividual diastereomers. Isomers shall be defined as being enantiomersand diastereomers. All such isomeric forms of these compounds areexpressly included in the present invention. Each stereogenic carbon maybe in the R or S configuration, or a combination of configurations.

Some of the compounds of the invention can exist in more than onetautomeric form. The invention includes methods using all suchtautomers.

All terms as used herein in this specification, unless otherwise stated,shall be understood in their ordinary meaning as known in the art. Forexample, “C₁₋₆ alkoxy” is a C₁₋₆ alkyl with a terminal oxygen, such asmethoxy, ethoxy, propoxy, butoxy. All alkyl, alkenyl, and alkynyl groupsshall be understood as being branched or unbranched where structurallypossible and unless otherwise specified. Other more specific definitionsare as follows:

The term “alkyl” refers to both branched and unbranched alkyl groups. Itshould be understood that any combination term using an “alk” or “alkyl”prefix refers to analogs according to the above definition of “alkyl”.For example, terms such as “alkoxy”, “alkythio” refer to alkyl groupslinked to a second group via an oxygen or sulfur atom. “Alkanoyl” refersto an alkyl group linked to a carbonyl group (C═O).

It shall be understood that if N is not substituted then it is NH. Asused herein, “nitrogen” and “sulfur” include any oxidized form ofnitrogen and sulfur and the quaternized form of any basic nitrogen. Forexample, for a —S—C₁₋₆ alkyl radical, unless otherwise specified, shallbe understood to include —S(O)—C₁₋₆ alkyl and —S(O)₂—C₁₋₆ alkyl.

The term “C₃₋₁₀ carbocycle” or “C₃₋₁₀ cycloalkyl” refers to anonaromatic 3 to 10-membered (but preferably, 3 to 6-membered)monocyclic carbocyclic/cycloalkyl radical or a nonaromatic 6 to10-membered fused bicyclic, bridged bicyclic, or spirocyclic carbocyclicradical. The C₃₋₁₀ carbocycle/cycloalkyl ring may be either saturated orpartially unsaturated, and the carbocycle/cycloalkyl ring may beattached by any atom of the cycle which results in the creation of astable structure. Non-limiting examples of 3 to 10-membered monocycliccarbocycles/cycloalkyl rings include cyclopropyl, cyclobutyl,cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl,cycloheptenyl, and cyclohexanone. Non-limiting examples of 6 to10-membered fused bicyclic carbocyclic/cycloalkyl radicals includebicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, and bicyclo[4.4.0]decanyl(decahydronaphthalenyl). Non-limiting examples of 6 to 10-memberedbridged bicyclic carbocyclic radicals include bicyclo [2.2.2]heptanyl,bicyclo[2.2.2]octanyl, and bicyclo[3.2.1]octanyl. Non-limiting examplesof 6 to 10-membered spirocyclic carbocyclic radicals include but are notlimited to spiro[3,3]heptanyl, spiro[3,4]octanyl and spiro[4,4]heptanyl.

The term “aryl” refers to aromatic hydrocarbon rings containing from sixto ten carbon ring atoms. The term aryl includes monocyclic rings andbicyclic rings where at least one of the rings is aromatic. Non-limitingexamples of C₆₋₁₀ aryls include phenyl, indanyl, indenyl,benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl,benzocycloheptanyl and benzocycloheptenyl.

The term “heterocycle” refers to a stable nonaromatic 4-8 memberedmonocyclic heterocyclic radical or a stable nonaromatic 6 to 11-memberedfused bicyclic, bridged bicyclic or spirocyclic heterocyclic radical.The 5 to 11-membered heterocycle consists of carbon atoms and one ormore, preferably from one to four heteroatoms chosen from nitrogen,oxygen and sulfur. The heterocycle may be either saturated or partiallyunsaturated. Non-limiting examples of nonaromatic 4-8 memberedmonocyclic heterocyclic radicals include tetrahydrofuranyl, azetidinyl,pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl,1,1-dioxo-1λ⁶-thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl,and azepinyl. Non-limiting examples of nonaromatic 6 to 11-memberedfused bicyclic radicals include octahydroindolyl, octahydrobenzofuranyl,and octahydrobenzothiophenyl. Non-limiting examples of nonaromatic 6 to11-membered bridged bicyclic radicals include2-azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.0]hexanyl, and3-azabicyclo[3.2.1]octanyl. Non-limiting examples of nonaromatic 6 to11-membered spirocyclic heterocyclic radicals include7-aza-spiro[3,3]heptanyl, 7-spiro[3,4]octanyl, and7-aza-spiro[3,4]octanyl.

The term “heteroaryl” shall be understood to mean an aromatic 5 to6-membered monocyclic heteroaryl or an aromatic 7 to 11-memberedheteroaryl bicyclic ring where at least one of the rings is aromatic,wherein the heteroaryl ring contains 1-4 heteroatoms such as N, O and S.Non-limiting examples of 5 to 6-membered monocyclic heteroaryl ringsinclude furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl,pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl,thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl,and purinyl. Non-limiting examples of 7 to 11-membered heteroarylbicyclic heteroaryl rings include benzimidazolyl, quinolinyl,dihydro-2H-quinolinyl, isoquinolinyl, quinazolinyl, indazolyl,thieno[2,3-d]pyrimidinyl, indolyl, isoindolyl, benzofuranyl,benzopyranyl, benzodioxolyl, benzoxazolyl, benzothiazolyl,dihydroindolyl, azaindolyl, benzothiazolyl, benzpyrrolyl, benzpyrazolyl,pyridopyrazolyl, dihydrobenzofuranyl, benzothienyl, benzodioxanyl,dihydrobenzo[1,4]dioxanyl and benzo[1,3]dioxolyl.

The term “heteroatom” as used herein shall be understood to mean atomsother than carbon such as O, N, and S.

The term “halogen” as used in the present specification shall beunderstood to mean bromine, chlorine, fluorine or iodine. Thedefinitions “halogenated”, “partially or fully halogenated”; partiallyor fully fluorinated; “substituted by one or more halogen atoms”,includes for example, mono, di or tri halo derivatives on one or morecarbon atoms. For alkyl, a non-limiting example would be —CH₂CHF₂, —CF₃etc.

Each alkyl, aryl, cycloalkyl/carbocycle, heterocycle or heteroaryl, orthe analogs thereof, described herein shall be understood to beoptionally partially or fully halogenated.

The compounds of the invention are only those which are contemplated tobe ‘chemically stable’ as will be appreciated by those skilled in theart. For example, a compound which would have a ‘dangling valency’, or a‘carbanion’ are not compounds contemplated by the inventive methodsdisclosed herein.

The invention includes pharmaceutically acceptable derivatives ofcompounds of formula (I). A “pharmaceutically acceptable derivative”refers to any pharmaceutically acceptable salt or ester, or any othercompound which, upon administration to a patient, is capable ofproviding (directly or indirectly) a compound useful for the invention,or a pharmacologically active metabolite or pharmacologically activeresidue thereof. A pharmacologically active metabolite shall beunderstood to mean any compound of the invention capable of beingmetabolized enzymatically or chemically. This includes, for example,hydroxylated or oxidized derivative compounds of the invention.

Pharmaceutically acceptable salts include those derived frompharmaceutically acceptable inorganic and organic acids and bases.Examples of suitable acids include hydrochloric, hydrobromic, sulfuric,nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic,salicylic, succinic, toluene-p-sulfuric, tartaric, acetic, citric,methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfuric andbenzenesulfonic acids. Other acids, such as oxalic acid, while notthemselves pharmaceutically acceptable, may be employed in thepreparation of salts useful as intermediates in obtaining the compoundsand their pharmaceutically acceptable acid addition salts. Salts derivedfrom appropriate bases include alkali metal (e.g., sodium), alkalineearth metal (e.g., magnesium), ammonium and N—(C₁-C₄ alkyl)₄ ⁺ salts.

In addition, within the scope of the invention is use of prodrugs ofcompounds of the invention. Prodrugs include those compounds that, uponsimple chemical transformation, are modified to produce compounds of theinvention. Simple chemical transformations include hydrolysis, oxidationand reduction. Specifically, when a prodrug is administered to apatient, the prodrug may be transformed into a compound disclosedhereinabove, thereby imparting the desired pharmacological effect.

The compounds of formula I may be made using the general syntheticmethods described below, which also constitute part of the invention.

SYNTHETIC EXAMPLES

List of abbreviations Ac cetyl ACN acetonitrile aq. aquatic, aqueous Boctert-butyloxycarbonyl Boc₂O di-tert-butyl dicarbonate Bu butyl dbaDibenzylideneacetone Davephos2-dimethylamino-2′-dicyclohexylaminophosphinobiphenyl DBAdibenzylideneacetone DCM dichloromethane DIPEA N,N-diisopropylethylamineDMAP 4-N,N-dimethylaminopyridine DMA N,N-dimethylacetamide DME1,2-dimethoxyethane DMF N,N-dimethylformamide DMSO dimethylsulphoxidedppf 1.1′-bis(diphenylphosphino)ferrocene EDC1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride equiv.equivalent(s) ESI electron spray ionization Et ethyl Et₂O diethyl etherEtOAc ethyl acetate EtOH ethanol h hour HATUO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyl-uroniumhexafluorophosphate hept heptane HOBt 1-hydroxybenzotriazole HPLC highperformance liquid chromatography conc. concentrated LiHMDS lithiumbis(trimethylsilyl)amide mCPBA 3-chloroperoxbenzoic acid Me methyl MeOHmethanol min minutes MS mass spectrometry MTBE methyl tertiary butylether NBS N-bromo-succinimide NIS N-iodo-succinimide NMPN-methylpyrrolidone Rt retention time (HPLC) rt ambient temperature TBAFtetrabutylammonium fluoride TBDMS tert-butyldimethylsilyl TBMEtert-butylmethylether TBTUO-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyl-uronium tetrafluoroboratetBu tertiary-butyl TEA triethylamine temp. temperature tert tertiary TFAtrifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatographyTsOH p-toluenesulphonic acid

GENERAL SYNTHETIC METHODS AND SYNTHESIS OF INTERMEDIATES

The compounds of the invention may be prepared by the methods andexamples presented below and methods known to those of ordinary skill inthe art. In each of the examples below, the groups R¹ to R⁷ are asdefined above for general formula I unless noted. Optimum reactionconditions and reaction times may vary depending on the particularreactants used. Unless otherwise specified, solvents, temperatures,pressures, and other reaction conditions may be readily selected by oneof ordinary skill in the art. Specific procedures are provided below.Intermediates used in the syntheses below are either commerciallyavailable or easily prepared by methods known to those skilled in theart. Reaction progress may be monitored by conventional methods such asthin layer chromatography (TLC) or high pressure liquidchromatography-mass spec (HPLC-MS). Intermediates and products may bepurified by methods known in the art, including column chromatography,HPLC, preparative TLC or Preparatory HPLC.

Intermediates Synthesis of 5-tert-butylsulfanyl-pyridin-2-ylamine (I-1)

To a mixture of 5-bromo-pyridin-2-ylamine (300 mg, 1.73 mmol) in DMSO (3mL) are added sodium 2-methyl-2-propanethiolate (388 mg, 3.47 mmol) andNaOH (35 mg, 0.87 mmol). The mixture is degassed with Ar for 20 min. Tothe reaction mixture are added L-proline (100 mg, 0.870 mmol) and CuI(330 mg, 1.73 mmol) and the reaction is heated to 120° C. for 12 h in asealed tube. The reaction is then cooled to room temperature, pouredinto ice water, and extracted with EtOAc (2×). The solvent is removedunder reduced pressure to provide 200 mg of crude5-tert-butylsulfanyl-pyridin-2-ylamine (I-1) that was used withoutfurther purification.

Synthesis of 5-tert-butylsulfanyl-pyrazolo[1,5-a]pyridine (I-2)

To a stirred solution of 5-bromo-pyrazolo[1,5-a]pyridine (2.0 g, 10.1mmol) in DME (30 mL), at 0° C., is added lithiumbis(trimethylsilyl)amide as a 1M solution in THF (24 mL, 25 mmol)). Inanother flask, palladium(II) acetate (227 mg, 1.01 mmol) and dppf (2.0g, 3.6 mmol) are combined in DME (30 mL) and stirred at room temperaturefor 10 min. The two solutions are then combined at room temperature, andtreated with 2-methyl-2-propanethiol (2.0 g, 22 mmol). The reaction isheated to 90° C. and stirred for 2 h. The reaction is then cooled toroom temperature, diluted with water, and extracted with EtOAc (2×). Theorganic layer is washed with brine, dried over Na₂SO₄, and concentratedunder reduced pressure. The residue is purified by flash silica gelcolumn chromatography to provide 1 g of5-tert-butylsulfanyl-pyrazolo[1,5-a]pyridine (I-2).

Synthesis of 6-(oxetan-3-ylsulfanyl)-imidazo[1,2-a]pyridine (I-3)

A mixture of 6-iodo-imidazo[1,2-a]pyridine (800 mg, 3.30 mmol), copperiodide (62 mg, 0.33 mmol), cesium carbonate (2.1 g, 6.6 mmol), NMP (8mL), and oxetane-3-thiol (325 mg, 3.6 mmol) is flushed with N₂ andsealed in a microwave reaction tube. The mixture is heated at 130° C.for 30 min in a microwave reactor. The reaction is cooled to roomtemperature, filtered through celite, and rinsed with EtOAc. Thefiltrate is diluted with water, and extracted with EtOAc (3×). Thecombined organic layers are washed with brine, dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The resulting residueis purified by flash silica gel column chromatography to provide 283 mgof 6-(oxetan-3-ylsulfanyl)-imidazo[1,2-a]pyridine (I-3).

The following intermediate is synthesized in a similar fashion asdescribed above using commercially available starting materials:

-   3-(Imidazo[1,2-a]pyridin-6-ylsulfanyl)-azetidine-1-carboxylic acid    tert-butyl (I-4)

Synthesis of 2-cyclopropyl-1-methyl-1H-imidazole (I-5)

To 4N HCl in dioxane (7.3 mL, 29 mmol) at 0° C. is slowly addedcylopropane carbonitrile (1 mL, 13.5 mmol) as a solution in anhydrousmethanol (1.2 mL). The mixture is stirred between 0-5° C. for 3 h duringwhich time a precipitate forms. The mixture is warmed to roomtemperature and the solution is concentrated under reduced pressure.MTBE (10 mL) is added, and the mixture is stirred for several minutes,then filtered to provide 783 mg of cyclopropanecarboximidic acid methylester HCl (I-5-1).

To a stirred suspension of I-5-1 (0.50 g, 3.9 mmol) in isopropanol (2.0mL) is added (2,2-dimethoxy-ethyl)-methyl-amine (0.50 mL, 4.0 mmol). Themixture becomes nearly homogeneous; then a gelatinous precipitate forms.The mixture is warmed to 80° C. for 4 h then is allowed to cool to roomtemperature and stirred for an additional 12 h. Concentrated HCl (1.1mL, 13 mmol) is then added and the mixture is heated to 80° C. for 45min. The mixture is cooled to room temperature, and poured into asaturated aqueous solution of NaHCO₃ (20 mL). The mixture is extractedwith EtOAc (3×) and the organic layer is washed with brine, dried overNa₂SO₄, filtered, and concentrated to provide 212 mg of2-cyclopropyl-1-methyl-1H-imidazole (I-5).

Synthesis of 3-bromo-6-(oxetan-3-ylsulfanyl)-imidazo[1,2-a]pyridine(I-6)

To a stirred solution of I-3 (242 mg, 1.20 mmol) in chloroform (4.2 mL)is added NBS (208 mg, 1.20 mmol). The reaction is stirred at roomtemperature for 30 min and then concentrated under reduced pressure. Theresulting residue is purified by flash silica gel column chromatographyto provide 294 mg of3-bromo-6-(oxetan-3-ylsulfanyl)-imidazo[1,2-a]pyridine (I-6).

The following intermediate is synthesized in a similar fashion asdescribed above usingI-4:3-(3-Bromo-imidazo[1,2-a]pyridine-6-sulfonyl)-azetidine-1-carboxylicacid tert-butyl ester (I-7)

The following intermediate is synthesized in a similar fashion asdescribed above using I-17:

-   3-Bromo-6-(morpholine-4-sulfonyl)-imidazo[1,2-a]pyridine (I-8)

The following intermediate is synthesized in a similar fashion asdescribed above using I-18

-   3-Bromo-6-methanesulfonyl-imidazo[1,2-a]pyridine (I-9)

The following intermediate is synthesized in a similar fashion asdescribed above using I-20

-   3-Bromo-6-tert-butylsulfanyl-imidazo[1,2-a]pyridine (I-10)

The following intermediate is synthesized in a similar fashion asdescribed above using I-23

-   3-Bromo-5-(2-methyl-propane-2-sulfonyl)-pyrazolo[1,5-a]pyridine    (I-11)

The following intermediate is synthesized in a similar fashion asdescribed above using I-16

-   3-Bromo-5-ethanesulfonyl-pyrazolo[1,5-a]pyridine (I-12)

The following intermediate is synthesized in a similar fashion asdescribed above using I-19

-   3-Bromo-6-(4-methyl-piperazine-1-sulfonyl)-imidazo[1,2-a]pyridine    (I-13)

The following intermediate is synthesized in a similar fashion asdescribed above using I-5

-   5-Bromo-2-cyclopropyl-1-methyl-1H-imidazole (I-14)

The following intermediate is synthesized in a similar fashion asdescribed above using I-32

-   3-Bromo-6-[1-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethyl]-imidazo[1,2-a]pyridine    (I-15)

Synthesis of 5-ethanesulfonyl-pyrazolo[1,5-a]pyridine (I-16)

To a stirred solution of ethylsulfanyl-pyridine (5.0 g, 36 mmol) inacetonitrile (50 mL), at 0° C., is added 2,4-di-nitrophenyl hydroxylamine (DNPH) (7.0 g, 35 mmol) in several portions. The reaction isslowly warmed to room temperature and then heated to 40° C. for 15 h.The reaction is concentrated under reduced pressure to provide 5.0 g of4-ethylsulfanyl-2H-pyridin-1-ylamine (I-16-1).

To a stirred solution of crude I-16-1 (5.0 g, 32 mmol) in DMF (50 mL),cooled to 0° C., is added K₂CO₃ (4.0 g, 29 mmol). To the reactionmixture is added, dropwise, ethyl propionate (3.0 g, 29 mmol) and thereaction is slowly warmed to rt. After 2 h, the reaction is diluted withwater and extracted with EtOAc (3×). The combined organic layer isconcentrated under reduced pressure to yield 2.0 g of crude5-ethylsulfanyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester(I-16-2).

To a stirred solution of I-16-2 (1.0 g, 4.0 mmol) in a mixture ofacetonitrile (5.0 mL) and water (10.0 mL), cooled to 0 C, is addedruthenium(III)chloride hydrate (826 mg, 4.0 mmol) and sodiummetaperiodate (2.0 mg, 9.0 mmol). After 30 minutes, the reaction isdiluted with water and extracted with EtOAc The organic layer isconcentrated under reduced pressure to provide 500 mg of the crude5-Ethanesulfonyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester(I-16-3).

To a stirred solution of sulfuric acid (2.0 g) in water (4.0 mL), at 0°C., is slowly added I-16-3 (1.0 g, 3.6 mmol). The reaction is stirred at90° C. for 2 h then cooled to room temperature. The pH of the mixture isadjusted to neutral by addition of a 2N NaOH solution and then extractedwith DCM (2×). The combined organic layers are washed with brine, driedover Na₂SO₄, and concentrated under reduced pressure. The residue ispurified by flash silica gel column chromatography to provide 298 mg of5-ethanesulfonyl-pyrazolo[1,5-a]pyridine (I-16).

Synthesis of 6-(morpholine-4-sulfonyl)-imidazo[1,2-a]pyridine (I-17)

A mixture of bromoacetaldehyde diethyl acetal (383 μL, 2.50 mmol) andaq. 2M HCl solution (1.4 mL, 2.7 mmol) is stirred at room temperaturefor 2 h. The reaction is then heated to 80° C. for 1 h. The reaction iscooled to 5° C. and the pH of the mixture adjusted to pH 8 by theaddition of solid sodium bicarbonate. To the reaction mixture is added5-(morpholine-4-sulfonyl)-pyridin-2-ylamine (300 mg, 1.2 mmol) and theresulting solution is warmed to room temperature and stirred overnight.The mixture is concentrated under reduced pressure and diluted withEtOAc (10 mL). The mixture is sonicated and filtered. The filtrate isconcentrated under reduced pressure and the resulting residue ispurified by flash silica gel column chromatography to provide 165 mg of6-(morpholine-4-sulfonyl)-imidazo[1,2-a]pyridine (I-17).

The following intermediates are synthesized in a similar fashion asdescribed above using commercially available material:

-   6-Methanesulfonyl-imidazo[1,2-a]pyridine (I-18)-   6-(4-Methyl-piperazine-1-sulfonyl)-imidazo[1,2-a]pyridine (I-19)

The following intermediate is synthesized in a similar fashion asdescribed above using I-1

-   6-tert-Butylsulfanyl-imidazo[1,2-a]pyridine (I-20)

Synthesis of3-(imidazo[1,2-a]pyridine-6-sulfonyl)-azetidine-1-carboxylic acidtert-butyl ester (I-21)

To a stirred solution of I-4 (480 mg, 1.6 mmol) in a mixture ofacetonitrile (20 mL) and water (10 mL), at room temperature, is addedruthenium(III) chloride hydrate (19 mg; 0.1 mmol) and sodiummetaperiodate (2.0 g, 9.4 mmol). After 1 h, the reaction is extractedwith EtOAc (3×), washed with brine, dried over Ns₂SO₄, and concentratedunder reduced pressure. The residue is purified by flash silica gelcolumn chromatography to afford 100 mg of3-(imidazo[1,2-a]pyridine-6-sulfonyl)-azetidine-1-carboxylic acidtert-butyl ester (I-21).

The following intermediate is synthesized according to the intermediatedescribed above using I-10:

-   3-Bromo-6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridine    (I-22)

The following intermediate is synthesized according to the intermediatedescribed above using I-2

-   5-(2-Methyl-propane-2-sulfonyl)-pyrazolo[1,5-a]pyridine (I-23)

Synthesis of3-bromo-7-methoxy-6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]-pyridine(I-24)

To a stirred solution of 4-methoxypyridin-2-ylamine (15 g, 121 mmol) inacetic acid (490 mL), at room temperature, is slowly added bromine as a1M solution in acetic acid (120 mL, 120 mmol). After 1.5 h, the reactionmixture is filtered and the collected solid is dissolved in EtOAc. Themixture is washed with saturated NaHCO₃ followed by water and thenbrine. The organic layer is dried over anhydrous Na₂SO₄, filtered, andthe filtrate is concentrated under reduced pressure to provide 15.1 g of5-bromo-4-methoxypyridin-2-ylamine (I-24-1).

To a stirred solution of I-24-1 (15 g, 74 mmol) in a 4:1 mixture ofethanol-water (150 mL) is added an aqueous solution ofchloroacetaldehyde (55% aqueous solution, 15 mL, 88.7 mmol) followed byaddition of solid NaHCO₃ (7.4 g, 89 mmol). The resulting solution isrefluxed for 4 h, then cooled to room temperature, diluted with water,and extracted with EtOAc (2×). The combined organic layer is dried overanhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. Theresidue is purified by flash silica gel column chromatography to provide10.6 g of 6-bromo-7-methoxy-imidazo[1,2-a]pyridine (I-24-2).

To a stirred suspension of I-24-2 (13 g, 56 mmol) in 1,4-dioxane (360mL) is added NaOtBu (6.6 g, 69 mmol) and 2-methyl-2-propanethiol (7.74g, 85.9 mmol). The resulting mixture is degassed with Ar for 5 min, thentreated with Pd(OAc)₂ (250 mg, 1.14 mmol) and dppf (760 mg, 1.37 mmol).The reaction is heated at 90° C. for 12 h then cooled to roomtemperature and filtered. The filtrate is diluted with water andextracted with EtOAc (3×). The combined organic layer is washed withwater followed by brine, then dried over anhydrous Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue is purified by flashcolumn chromatography to provided 10.4 g of6-tert-butylsulfanyl-7-methoxy-imidazo[1,2-a]pyridine (I-24-3).

To a stirred solution of I-24-3 (6.0 g, 25 mmol) in a 1:1 mixture ofMeOH:water (60 mL), at 0° C., is added Oxone® (47 g, 76 mmol). Theresulting mixture is allowed to stir with warming to room temperatureover 1 h. The mixture is filtered and the filter pad is washed withEtOAc. The pH of the combined filtrate is adjusted to neutral byaddition of a saturated solution of NaHCO₃ then extracted with EtOAc.The combined organic layer is washed with water, dried over anhydrousNa₂SO₄, filtered, and concentrated under reduced pressure. The residueis purified by flash silica gel column chromatography to provide 6.0 gof 7-methoxy-6-(2-methyl-propane-2 sulfonyl) imidazole[1,2-a] pyridine(I-24-4).

To a stirred solution of I-24-4 (6.0 g, 18.6 mmol) in DMF (30 mL) isadded NBS (3.3 g, 18.6 mmol). The resulting mixture is stirred at roomtemperature for 30 min, then diluted with water and extracted withEtOAc. The organic layer is washed with water (4×) followed by brinethen dried over anhydrous Na₂SO₄, filtered, and concentrated underreduced pressure. The residue is purified by flash silica gel columnchromatography to provide 5.5 g of3-bromo-7-methoxy-6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridine(I-24).

Synthesis of 3-bromo-imidazo[1,2-a]pyridine-6-carboxylic acidmethylamide (I-25)

To a stirred solution of 3-bromo-imidazo[1,2-a]pyridine-6-carboxylicacid (130 mg, 0.540 mmol) in DMF (2.1 mL), at room temperature, is addedEt₃N (376 μL, 2.7 mmol) followed by a solution of methylamine in EtOH(33 wt %, 101 mg, 1.1 mmol), and HATU (308 mg, 0.81 mmol). The reactionis stirred at room temperature for 18 h then diluted with water andextracted with EtOAc (3×). The organic layer is washed with waterfollowed by brine then dried over Na₂SO₄, filtered, and concentratedunder reduced pressure. The resulting residue is purified by flashsilica gel chromatography to provide 83 mg of3-bromo-imidazo[1,2-a]pyridine-6-carboxylic acid methylamide.

The following intermediate is synthesized in a similar fashion asdescribed above using a commercially available amine:

-   3-Bromo-imidazo[1,2-a]pyridine-6-carboxylic acid dimethylamide    (I-26)

Synthesis of 5-bromo-thiazole-2-carboxylic acid amide (I-27)

To a stirred solution of 5-bromo-thiazole-2-carboxylic acid ethyl ester(100 mg, 0.42 mmol) is added to a 7M solution of ammonia in MeOH (3.0ml, 21 mmol). The reaction is stirred at 80° C. for 12 h in a sealedtube then cooled to room temperature and concentrated under reducedpressure to provide 88 mg of 5-bromo-thiazole-2-carboxylic acid amide(I-28).

The following intermediate is synthesized in a similar fashion asdescribed above using a commercially available amine:

-   5-Bromo-thiazole-2-carboxylic acid methylamide (I-29)

Synthesis of3-bromo-6-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-imidazo[1,2-a]pyridine(I-30)

To a stirred solution of 6-iodo-imidazo[1,2-a]pyridine (3.8 g, 16 mmol)in THF (204 mL) at −20° C. is added iPrMgCl*LiCl as a 1.3 M solution inTHF (14.5 mL, 18.8 mmol). After stirring for 20 min, a solution of 5Macetaldehyde in THF (4.1 mL, 20 mmol) is added. The reaction is stirredfor 5 min at −20° C. and then the cold bath is removed and the mixtureis allowed to warm to room temperature. After 1.5 h, the reaction isdiluted with saturated aqueous sodium bicarbonate solution (2 mL) thenconcentrated under reduced pressure. The resulting residue is purifiedby flash silica gel column chromatography to provide 2.1 g of1-imidazo[1,2-a]pyridin-6-yl-ethanol (I-30-1).

A mixture of I-30-1 (3.0 g, 18.5 mmol), TBDMSCl (4.0 g; 27 mmol), andimidazole (2.0 g, 30 mmol) are dissolved in a 9:1 mixture of DMF:DCM (60mL). The reaction is stirred at room temperature for 3 h thenconcentrated under reduced pressure. The resulting residue is purifiedby flash silica gel column chromatography to provide 4.26 g of6-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-imidazo[1,2-a]pyridine(I-30-2).

To a stirred solution of I-30-2 (4.3 g, 15 mmol) in chloroform (55 mL),at room temperature, is added NBS (2.7 g, 15 mmol). After 25 min, thereaction is diluted with saturated NaHCO₃ solution and extracted withEtOAc (3×). The combined organic layers are washed with brine, driedover anhydrous Na₂SO₄, and concentrated under reduced pressure. Theresidue is purified by flash silica gel chromatography to provide 5.3 gof3-bromo-6-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-imidazo[1,2-a]pyridine(I-30).

The following intermediate is synthesized in a similar fashion asdescribed above using a commercially available aldehyde:

-   3-Bromo-6-[(tert-butyl-dimethyl-silanyloxy)-(tetrahydro-pyran-4-yl)-methyl]-imidazo[1,2-a]pyridine    (I-31)

Synthesis of 2-Imidazo[1,2-a]pyridin-6-yl-propan-2-ol (I-31)

To a stirred solution of 1-imidazo[1,2-a]pyridin-6-yl-ethanone (710 mg,4.4 mmol) in THF (35 mL), at −78° C., is added MeMgBr as a solution inTHF (3M, 1.6 mL, 4.8 mmol). The mixture is allowed to warm to roomtemperature overnight. The mixture is then quenched with saturated NH₄Clsolution, extracted with EtOAc (3×), and concentrated under reducedpressure. The residue is purified by flash silica gel columnchromatography to provide 576 mg of2-imidazo[1,2-a]pyridin-6-yl-propan-2-ol (I-31).

Synthesis of6-[1-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethyl]-imidazo[1,2-a]pyridine(I-32)

To a stirred solution of I-31 (467 mg, 2.70 mmol) in THF (6.0 mL), atroom temperature, is added, dropwise, KHMDS as a solution in toluene(0.5 M, 5.3 mL, 2.6 mmol). To this mixture is added a solution ofTBDMSCl (400 mg, 2.65 mmol) in THF (4 mL). After 1.5 h, the reaction isdiluted with water and extracted with EtOAc (3×). The organic layer iswashed with brine, dried over Na₂SO₄, filtered, and concentrated. Theresidue is purified by flash silica gel column chromatography to yield400 mg of6-[1-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethyl]-imidazo[1,2-a]pyridine(I-32).

Synthesis of3-bromo-5-(2-methyl-propane-2-sulfinyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine(I-33)

To a mixture of 3-bromo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazinehydrochloride (0.90 g, 3.8 mmol) and triethylamine (2.3 g, 22.6 mmol) inanhydrous dichloromethane (20 mL), at 0° C., is added2-methyl-propane-2-sulfinyl chloride (1.3 g, 9.4 mmol). After stirringfor 16 hours, the reaction is diluted with water (5 mL) and extractedwith DCM (3×). The combined organic extracts are dried (Na₂SO₄),filtered and concentrated under reduced pressure. The residue ispurified by flash silica gel chromatography to afford 0.9 g of3-bromo-5-(2-methyl-propane-2-sulfinyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine(I-33).

Synthesis of3-bromo-5-(2-methyl-propane-2-sulfonyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine(I-34)

To a solution of I-33 (0.9 g, 2.9 mmol) in anhydrous DCM (20 mL) isadded mCPBA (0.76 g, 4.4 mmol). After stirring for 16 h, saturatedaqueous sodium sulfite (2 mL) is added and the reaction is stirred for30 minutes. The reaction is then extracted with DCM (3×20 mL) and thecombined organic extracts are dried (Na₂SO₄), filtered, and concentratedunder reduced pressure. The residue is purified by flash silica gelchromatography to afford 0.7 g of3-bromo-5-(2-methyl-propane-2-sulfonyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine(I-34).

Synthesis of 3-bromo-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine (I-35)

To a stirred solution of 2-chloro-4-nitro-pyridine (8.0 g, 50 mmol) in2-methoxyethanol (9.9 mL, 130 mmol), at 0° C., is added KOt-Bu (6.2 g,55 mmol) in several portions. After addition, the reaction mixture isstirred at ambient temperature for 3 h. The reaction mixture ispartitioned between DCM and water, and then the layers are separated.The aqueous layer is extracted with EtOAc (2×) and the combined organiclayer is washed with brine, dried over anhydrous MgSO₄, and concentratedunder reduced pressure to afford 5.2 g of2-[(2-chloro-4-pyridyl)oxy]ethanol (I-35-1) which is used in subsequentsteps without further purification.

A mixture of I-35-1 (2.9 g, 15 mmol), Pd₂(dba)₃ (0.28 g, 0.31 mmol), andX-Phos (0.29 g, 0.62 mmol) in dry THF (30 mL) is degassed with argon for10-15 min. To this mixture is added, dropwise, solution of LiHMDS in THF(32.5 mL, 32.6 mmol, 1M). The resulting mixture is then heated to 60° C.After 18 h, the reaction mixture is cooled to rt and 1M HCl (20 mL, 20mmol) is added. The resulting solution is washed with MTBE (50 mL) andthe organic layer is separated. The aqueous layer is made basic to pH˜11 by addition of a 6M aqueous NaOH solution, and then extracted withEtOAc (3×). The combined organic layer is washed with water, dried overanhydrous MgSO₄, and concentrated under reduced pressure to afford 2.1 gof 2-[(2-amino-4-pyridyl)oxy]ethanol (I-35-2) which is used insubsequent steps without further purification.

To a stirred solution of I-35-2 (4.0 g, 24 mmol) in THF (40 mL) is addedan aqueous solution of 2-chloroacetaldehyde (6.8 g, 48 mmol, 55% aqueoussolution). The mixture is heated to 75° C. in a sealed tube for 18 h.The mixture is then cooled to ambient temperature and partitionedbetween EtOAc (3×50 mL) and saturated aqueous NaHCO₃ (100 mL). Thecombined organic layer is washed with brine (100 mL), dried overanhydrous MgSO₄, and concentrated under reduced pressure to afford 1.8 gof 7-(2-methoxyethoxy)imidazo[1,2-a]pyridine (I-35-3) which is used insubsequent steps without further purification.

To a stirred solution of I-35-3 (1.3 g, 6.8 mmol) in DMF (15 mL) isadded NBS (1.2 g, 6.8 mmol) in one portion. The resulting mixture isstirred at ambient temperature for 5 min then diluted with saturatedaqueous sodium thiosulphate (150 mL) and then extracted with EtOAc (3×50mL). The combined organic layer is washed with brine, dried overanhydrous MgSO₄, concentrated under reduced pressure. The residue ispurified by flash silica gel column chromatography to afford 1.1 g of3-bromo-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine (I-35).

Synthesis of N-Cyclopropyl-4-methyl-3-(1H-pyrazol-4-yl)benzamide (I-36)

To a stirred solution of 3-iodo-4-methyl-benzoic acid (42 g, 160 mmol)in DMF (400 mL), at room temperature, is added EDC HCl (92 g, 481 mmol)followed by HOBt (32 g, 240 mmol). The reaction mixture is stirred for30 min followed by the addition of cyclopropylamine (13.3 mL, 192 mmol)and DIPEA (140 mL, 802 mmol). After 16 h, the reaction is quenched withwater and extracted with EtOAc. The combined organic layer is washedwith brine, dried over anhydrous MgSO₄, and evaporated under reducedpressure. The crude material is washed with 20% EtOAc in hexane (200 mL)to afford 45 g of N-cyclopropyl-3-iodo-4-methyl-benzamide (I-36-1).

To a solution of I-36-1 (20 g, 66.4 mmol) in 1,4-dioxane (500 mL), atambient temperature, is added tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate(23.4 g, 79.7 mmol) followed by Na₂CO₃ (21.1 g, 199 mmol) and water (150mL). The reaction mixture is degassed and refilled with nitrogen twotimes. PdCl₂(dppf) (5.4 g, 6.6 mmol) is added and the reaction mixtureis heated at 110° C. for 4 h. The reaction mixture is cooled andevaporated under reduced pressure. The crude residue is purified byflash column chromatography on silica gel (eluent with 3% MeOH in EtOAc)to yield 15.2 g of N-cyclopropyl-4-methyl-3-(1H-pyrazol-4-yl)benzamide(I-36).

The following intermediates are synthesized according to the generalprocedure described above using commercially available benzoic acids:

-   N-Cyclopropyl-2-fluoro-4-methyl-5-(1H-pyrazol-4-yl)benzamide (I-37)-   4-Chloro-N-cyclopropyl-2-fluoro-5-(1H-pyrazol-4-yl)benzamide (I-38)

Starting benzoic acid for the synthesis of intermediate I-37 is made thefollowing way:

Synthesis of 2-fluoro-5-iodo-4-methyl-benzoic acid (I-1A)

To a stirred solution of 2-fluoro-4-methyl benzoic acid (26 g, 168 mmol)in concentrated H₂SO₄ (260 mL) is dropwise added freshly preparednitration mixture [concentrated H₂SO₄ (10.7 mL)+70% HNO₃ (11.9 mL)] at0° C. over 45 min. The resultant solution is stirred for 3 h at 0° C.The reaction mixture is quenched with ice water. The resultingheterogeneous solution is extracted with ethyl acetate. The combinedorganic layer is washed with water, brine, dried over anhydrous MgSO₄,filtered and concentrated under reduced pressure to afford 30 g of crude2-fluoro-4-methyl-5-nitro-benzoic acid (I-1-1).

To a stirred solution of I-1-1 (30 g, 150 mmol) in methanol (300 mL) isadded thionyl chloride (22.5 mL, 301 mmol) dropwise at 10° C. Theresultant solution is warmed to reflux. After 12 h, the solvent isconcentrated under reduced pressure and the crude residue is partitionedbetween ethyl acetate and water. The organic layer is separated andwashed with saturated NaHCO₃ solution, water, brine, dried overanhydrous MgSO₄, filtered and concentrated under reduced pressure toafford 30 g of methyl 2-fluoro-4-methyl-5-nitro-benzoate (I-1-2).

The solution of methyl I-1-2 (30 g, 141 mmol) in methanol (600 mL) wascharged to a 2 liter Parr pressure vessel. Palladium, 10% on carbon (3g, 28 mmol), is then added under nitrogen atmosphere. The Parr vessel isput under a hydrogen atmosphere (45 psi). After 12 h, the reaction massis filtered through celite and the filtrate is concentrated underreduced pressure to afford 26 g of methyl5-amino-2-fluoro-4-methyl-benzoate (I-1-3).

To a stirred solution of I-1-3 (26 g, 142 mmol) in acetonitrile (540 mL)at −5° C. is dropwise added isoamyl nitrite (21.7 g, 184 mmol). After 5min, copper (I) iodide (56 g, 369 mmol) is added portion wise to thereaction mixture and the resultant mixture is slowly heated to 65° C.for 2 h. The solution is filtered through celite and the filtrate isconcentrated under reduced pressure. Flash column chromatography(silical gel, eluent with 5% ethyl acetate in hexane) yields 20 g ofmethyl 2-fluoro-5-iodo-4-methyl-benzoate (I-1-4).

To a stirred solution of I-1-4 (20 g, 68 mmol) in THF:MeOH:H₂O (1:1:1,300 mL) is added solid NaOH (4 g, 102 mmol) at room temperature. Theresultant solution is stirred for 3 h at room temperature. The solventis concentrated under reduced pressure and the residue is diluted withwater (500 mL) and washed with ethyl acetate (2×150 mL). The pH of theaqueous layer is adjusted to pH 2 by addition of 10% aqueous HCl andthen extracted with DCM (3×150 mL). The combined organic layer is washedwith water (2×100 mL), brine (200 mL), dried over anhydrous MgSO₄,filtered and concentrated under reduced pressure to afford2-fluoro-5-iodo-4-methyl-benzoic acid (I-1A).

Synthesis of Synthesis ofN-Cyclopropyl-3-(1H-imidazol-4-yl)-4-methyl-benzamide (I-39)

A mixture ofN-Cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide(1.0 g; 3.2 mmol), 4-Bromo-1-trityl-1H-imidazole (1.4 g; 3.54 mmol), 2MK2CO3 solution in water (4.0 ml; 8.05 mmol), andtetrakis(triphenylphosphine)palladium(0) (428.0 mg; 0.37 mmol) inDioxane (13.4 ml) is degassed and refilled with nitrogen in a microwavevial. The reaction is heated in a microwave reactor at 130° C. for 30min. The mixture is diluted with water and extracted with EtOAc. Theorganic phase is washed with brine, dried over Na2SO4, filtered, andconcentrated under reduced pressure. The resulting residue is purifiedby flash silica gel chromatography to provideN-Cyclopropyl-4-methyl-3-(1-trityl-1H-imidazol-4-yl)-benzamide I-39-1(1.0 g).

To a solution of I-39-1 (1 g; 2.1 mmol) in dichloromethane (11.7 ml) isadded TFA (2.0 ml). The mixture is stirred at rt for 2 h. An additional0.5 mL of TFA was added and the reaction is stirred for another 1 h. ThepH of the mixture is adjusted to pH 8 by the addition of a sat. solutionof NaHCO3. The mixture washed with brine, dried over Na2SO4, filtered,and concentrated under reduced pressure. The resulting residue ispurified by flash slica gel column chromatography to provide the titlecompound (I-39) (500 mg).

The following intermediates are synthesized according to the generalprocedure described above using commercially available benzoic acids:

-   N-Cyclopropyl-2-fluoro-4-methyl-5-(1H-imidazol-4-yl)benzamide    (I-39-2)

Synthesis of 3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic aciddimethylamide (I-40)

To a solution of 4-Methoxy-pyridin-2-ylamine (45 g; 0.362 mol; 1.0 eq.)in HOAc (1000 mL) is added a solution of Br₂ (57.9 g; 0.362 mol; 1.0eq.) in HOAc (260 mL) dropwise within 0.5 h. A large amount of whitesolid is generated. The resultant mixture is stirred at 18° C. for 1.5h. After filtration, the filter cake is taken up with EtOAc (1500 mL)and washed with sat. NaHCO₃ (500 mL×2), water (300 mL) and brine (200mL), dried over Na₂SO₄, filtered and concentrated to afford5-Bromo-4-methoxy-pyridin-2-ylamine (53.0 g; 0.261 mol) as a whitesolid, which is used in next step without purification.

To a solution of 5-Bromo-4-methoxy-pyridin-2-ylamine (53 g, 0.261 mol,1.0 eq.) in EtOH:H2O=4:1 (500 mL) is added chloro-acetaldehyde (24.589g, 0.313 mol, 1.2 eq.), then NaHCO₃ (26.3 g, 0.313 mol, 1.2 eq.) isadded. The resultant mixture is heated to 90° C. for 4 h. After coolingto r.t., the organic solvent is evaporated. The residue is extractedwith DCM (200 mL×3). The organic layer are combined, dried over Na₂SO₄,filtered and concentrated. The crude product is purified by silica gelchromatography (DCM:MeOH=50:1) to afford compound6-Bromo-7-methoxy-imidazo[1,2-a]pyridine (39 g, 66%) as a brown solid.

To a solution of 6-Bromo-7-methoxy-imidazo[1,2-a]pyridine (34.9 g, 0.154mol, 1.0 eq.) in MeOH (350 ml) and Toluene (350 ml) is added TEA (23 g,0.231 mol, 1.5 eq.), then Pd(dppf)Cl₂ (11.2 g, 0.015 mol, 0.1 eq.) isadded under N₂ atmosphere. The resultant mixture is heated to 80° C.under CO atmosphere (3 MPa) for 16 h. The solvent is removed undervacuum. The residue is purified by column chromatography (DCM) andwashed with PE:EA=1:1 (20 mL) to afford7-Methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (20 g,63%) as a brown solid.

To a solution of 7-Methoxy-imidazo[1,2-a]pyridine-6-carboxylic acidmethyl ester (20 g, 97 mmol, 1.0 eq.) in CHCl₃ (400 ml) is added NBS (17g, 97 mmol, 1.0 eq.) at −10° C. under N₂ atmosphere. The resultantsolution is allowed to warm to 0° C. and stirred for 20 min. Afterdiluted with DCM (400 mL), the resultant solution is washed with water(200 mL×2) and brine (300 mL). The organic layer is separated, driedover Na₂SO₄, filtered and concentrated. The residue is washed with amixture solvent PE:EA=1:1 (500 mL) and DCM (100 mL) to afford compound3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester(15.5 g, 54 mmol) as a pale solid.

3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester(2 g, 7 mmol) is dissolved in THF (40 mL), then 3.5 mL of aq. 6N HCl isadded. The mixture is heated at 60° C. for 2 days. Additional 3.5 mL of6N HCl is added. The reaction is heated for another day. After coolingdown to rt, solvent is evaporated to afford the crude product3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid as an HCLsalt (2.2 g, 60%).

The above HCl salt of3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid (2.2 g) isneutralize with Sat. NaHCO₃ until pH=7. The solid is filtered and rinsedwith water. The solid is dried under high vacuum. It is then dissolvedin DMF (20 mL), Et₃N (3 mL, 21 mmol) and dimethylamine HCl (700 mg, 8.6mmol) are added, followed by HATU (2.4 g, 6.4 mmol). Stirring iscontinued at room temperature overnight. To the reaction is added water,extracted with EtOAc, washed with water, brine, dried over Na₂SO₄,filtered and concentrated. The residue is purified by silica gelchromatrography (0-10% MeOH in DCM) to afford compound3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid dimethylamide(I-40) (1.24 g, 76%).

Synthesis ofN-Cyclopropyl-2-fluoro-4-methyl-5-[1-(6-piperidin-4-yl-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-benzamidedi-hydrochrolide (I-41)

To a mixture of 6-Bromo-imidazo[1,2-a]pyridine (20 g, 0.102 mol, 1.0eq), boronic ester (37.66 g, 0.122 mol, 1.2 eq) and Cs₂CO₃ (65.98 g,0.203 mol, 2.0 eq) in Dioxane (300 mL) and H₂O (30 mL) is addedPd(PPh₃)₂Cl₂ (7.13 g, 0.01 mol, 0.1 eq) at room temperature under N₂.The mixture is heated to 100° C. and stirred for 15 h under N₂. TLC andLCMS showed the reaction is completed. The reaction is filtered througha pad of celite and washed with DCM (3×500 mL). The filtrate isconcentrated in vacuo to give the crude product, which is purified bysilica gel column chromatography (DCM:MeOH=100:1 to 30:1) to afford4-Imidazo[1,2-a]pyridine-6-yl-3,6-dihydro-2H-pyridine-1-carboxylic acidtert-butyl ester (26 g, 0.087 mol) as a brown oil.

To a solution of4-Imidazo[1,2-a]pyridine-6-yl-3,6-dihydro-2H-pyridine-1-carboxylic acidtert-butyl ester (52 g, 173.7 mmol, 1.0 eq.) in MeOH (3000 mL) is added10% Pd/C (20 g) under Ar₂. The reaction mixture is stirred under H₂ (50psi) at 20° C. for 10 h. The mixture is filtered through a celite padand washed with MeOH (1500 mL), the filtrate is concentrated in vacuo togive the crude product, which is purified by silica gel columnchromatography (DCM:MeOH=300:1 to 20:1) to4-Imidazo[1,2-a]pyridine-6-yl-piperidine-1-carboxylic acid tert-butylester (50 g, 165.9 mmol) as a brown oil.

To a stirred solution of4-Imidazo[1,2-a]pyridine-6-yl-piperidine-1-carboxylic acid tert-butylester (1.5 g, 5 mmol) in chloroform (15 mL) is added NBS (890 mg, 5mmol). The solution is stirred at room temperature for 2 h and thenconcentrated. The residue is diluted with EtOAc, washed with NaHCO₃,H₂O, brine and concentrated to give a residue, which is purified byflash chromatography (25 g, 0-80% EtOAc/heptane), followed by reversephase chromatography (100 g, 10-100% H2O/ACN, both containing 0.5%formic acid) to afford compound4-(3-Bromo-imidazo[1,2-a]pyridine-6-yl)-piperidine-1-carboxylic acidtert-butyl (1.6 g, 85%).

4-(3-Bromo-imidazo[1,2-a]pyridine-6-yl)-piperidine-1-carboxylic acidtert-butyl (1.55, 4.1 mmol), I-37 (1.3 g, 4.9 mmol), CuI (388 mg, 2.0mmol), K₃PO₄ (1.7 g, 8.2 mmol) and trans-dimethylaminocyclohexane (463mg, 3.3 mmol) are suspended in DMF (15 mL) and the mixture is flushedwith Ar. The mixture is then heated to 65° C. and allowed to stirovernight. The mixture is cooled to room temperature, diluted withEtOAc, washed with H₂O, brine and concentrated to give a residue, whichis purified by flash chromatography (50 g, 0-100% EtOAc/heptane) toafford compound4-{3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-yl}-piperidine-1-carboxylicacid tert-butyl ester (1.4 g, 62%).

To a stirred and cooled (0° C.) solution of4-{3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-yl}-piperidine-1-carboxylicacid tert-butyl ester (1.4 g, 2.5 mmol) in DCM (15 mL) and MeOH (5 mL)is added 4N HCl in dioxane (10 mL). The mixture is allowed to warm toroom temperature overnight. The solution is concentrated to give aresidue, which is dried in vacuum to afford compound I-41 (1.32 g, 99%)

Final Compounds

Example 13-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylicacid dimethylamide

I-40 (217 mg, 0.7 mmol), I-37 (170 mg, 0.7 mmol), CuI (50 mg, 0.3 mmol),K₃PO₄ (278 mg, 1.3 mmol) and trans-dimethylaminocyclohexane (74 mg, 0.5mmol) are suspended in DMF (10 mL) and the mixture flushed with Ar. Themixture is then heated to 60° C. for 6 h, then at room temperatureovernight. The reaction is filtered, rinsed with EtOAc and concentrated.To the residue is added water, extracted with EtOAc, washed with waterand concentrated. The residue is purified by reverse phase HPLC (5-50%%ACN in water with formic acid). Pure fractions are combined andconcentrated. The residue is dissolved in MeOH and passed through abicarbonate cartridge to afford 1 as a white solid (75 mg, 24%).

Example 23-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylicacid methyl ester

A mixture of 3-bromo-imidazo[1,2-a]pyridine-6-carboxylic acid methylester (492 mg, 1.93 mmol), I-37 (500 mg, 1.93 mmol), potassium phosphate(819 mg, 3.86 mmol), trans-N,N′-dimethyl-cyclohexane-1,2-diamine (0.2ml, 1.54 mmol) in anhydrous DMF (8.0 ml) is degassed with nitrogen. Tothis mixture is added CuI (147 mg, 0.77 mmol). The reaction is placedunder nitrogen and the reaction is heated at 60° C. for 4 h. The mixtureis then cooled to room temperature and stirred for 18 h. The reaction isthen diluted with water and extracted with EtOAc (3×). The organiclayers are combined, washed with water, then brine, and dried oversodium sulfate. The solution is then filtered and concentrated underreduced pressure. The resulting residue is purified by flash silica gelchromatography to provide 374 mg of the title compound (2).

The following compounds are synthesized in a similar fashion to Example2 using commercially available heteroaryl bromide and/or intermediatesdescribed herein:

-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-imidazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid methylamide (3)-   4-Chloro-N-cyclopropyl-2-fluoro-5-(1-imidazo[1,2-a]pyridin-3-yl-1H-pyrazol-4-yl)-benzamide    (5)-   4-Chloro-N-cyclopropyl-2-fluoro-5-(1-imidazo[1,2-a]pyrazin-3-yl-1H-pyrazol-4-yl)-benzamide    (6)-   5-[1-(2-Acetylamino-thiazol-5-yl)-1H-pyrazol-4-yl]-4-chloro-N-cyclopropyl-2-fluoro-benzamide    (7)-   5-[1-(8-Amino-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-4-chloro-N-cyclopropyl-2-fluoro-benzamide    (8)-   4-Chloro-N-cyclopropyl-2-fluoro-5-[1-(6-methoxy-imidazo[1,2-a]pyrazin-3-yl)-1H-pyrazol-4-yl]-benzamide    (9)-   4-Chloro-N-cyclopropyl-2-fluoro-5-{1-[6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (10)-   4-Chloro-N-cyclopropyl-2-fluoro-5-(1-pyrazolo[1,5-a]pyridin-3-yl-1H-pyrazol-4-yl)-benzamide    (11)-   4-Chloro-N-cyclopropyl-2-fluoro-5-(1-imidazo[1,2-a]pyrazin-6-yl-1H-pyrazol-4-yl)-benzamide    (12). Note: Obtained as a side-product starting from    6-bromo-3-iodo-imidazo[1,2-a]pyrazine, and reaction is conducted at    100° C. for 18 h.-   N-Cyclopropyl-3-(1-imidazo[1,2-a]pyrazin-3-yl-1H-pyrazol-4-yl)-4-methyl-benzamide    (13)-   3-[1-(2-Acetylamino-thiazol-5-yl)-1H-pyrazol-4-yl]-N-cyclopropyl-4-methyl-benzamide    (14)-   N-Cyclopropyl-3-(1-imidazo[1,2-a]pyridin-3-yl-1H-pyrazol-4-yl)-4-methyl-benzamide    (15)-   3-[1-(2-Acetylamino-thiazol-5-yl)-1H-imidazol-4-yl]-N-cyclopropyl-4-methyl-benzamide    (17)-   N-Cyclopropyl-4-methyl-3-{1-[6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (19)-   N-Cyclopropyl-4-methyl-3-{1-[6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-2-yl]-1H-pyrazol-4-yl}-benzamide    (20). Note: Obtained as a side-product from synthesis of 19 when    reaction is conducted at 100° C. for 18 h.-   4-Chloro-N-cyclopropyl-2-fluoro-5-[1-(6-methanesulfonyl-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-benzamide    (21)-   N-Cyclopropyl-4-methyl-3-{1-[6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-imidazol-4-yl}-benzamide    (22)-   N-Cyclopropyl-4-methyl-3-{1-[6-(oxetan-3-ylsulfanyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (23)-   5-[4-(2-Chloro-5-cyclopropylcarbamoyl-4-fluoro-phenyl)-pyrazol-1-yl]-thiazole-2-carboxylic    acid amide (25)-   5-[4-(2-Chloro-5-cyclopropylcarbamoyl-4-fluoro-phenyl)-pyrazol-1-yl]-thiazole-2-carboxylic    acid methylamide (26)-   N-Cyclopropyl-3-[1-(6-ethanesulfonyl-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (27)-   N-Cyclopropyl-3-{1-[7-methoxy-6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-2-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide    (28). Note: Obtained as a side-product during synthesis of 35 when    reaction is conducted at 100° C. for 18 h.-   N-Cyclopropyl-4-methyl-3-{1-[5-(2-methyl-propane-2-sulfonyl)-pyrazolo[1,5-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (29)-   N-Cyclopropyl-3-[1-(6-ethanesulfonyl-7-methoxy-imidazo[1,2-a]pyridin-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (30). Note: Obtained as a side-product when reaction is conducted at    100° C. for 18 h.-   N-Cyclopropyl-3-[1-(7-ethoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (31)-   N-Cyclopropyl-2-fluoro-5-(1-imidazo[1,2-a]pyridin-3-yl-1H-pyrazol-4-yl)-4-methyl-benzamide    (32)-   N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (33)-   N-Cyclopropyl-2-fluoro-5-[1-(6-methoxy-imidazo[1,2-a]pyrazin-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (34)-   N-Cyclopropyl-3-{1-[7-methoxy-6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide    (35)-   N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(morpholine-4-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (36)-   N-Cyclopropyl-4-methyl-3-{1-[6-(morpholine-4-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (37)-   N-Cyclopropyl-4-methyl-3-{1-[6-(4-methyl-piperazine-1-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (38)-   N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(4-methyl-piperazine-1-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (39)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-imidazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid dimethylamide (41)-   3-(1′-tert-Butyl-1′H-[1,4′]bipyrazolyl-4-yl)-N-cyclopropyl-4-methyl-benzamide    (42)-   N-Cyclopropyl-4-methyl-3-(1-thiazol-5-yl-1H-pyrazol-4-yl)-benzamide    (43)-   3-[1-(2-Cyclobutoxy-thiazol-5-yl)-1H-pyrazol-4-yl]-N-cyclopropyl-4-methyl-benzamide    (44)-   3-{1-[2-(Cyclopropanecarbonyl-amino)-thiazol-5-yl]-1H-pyrazol-4-yl}-N-cyclopropyl-4-methyl-benzamide    (45)-   N-Cyclopropyl-4-methyl-3-[1-(2-morpholin-4-yl-thiazol-5-yl)-1H-pyrazol-4-yl]-benzamide    (46)-   N-Cyclopropyl-4-methyl-3-[1-(2-phenyl-thiazol-5-yl)-1H-pyrazol-4-yl]-benzamide    (47)-   N-Cyclopropyl-4-methyl-3-{1-[2-(2-oxo-2H-pyridin-1-yl)-thiazol-5-yl]-1H-pyrazol-4-yl}-benzamide    (48)-   N-Cyclopropyl-4-methyl-3-[1-(2-pyrrolidin-1-yl-thiazol-5-yl)-1H-pyrazol-4-yl]-benzamide    (49)-   N-Cyclopropyl-4-methyl-3-[1-(2-piperidin-1-yl-thiazol-5-yl)-1H-pyrazol-4-yl]-benzamide    (50)-   N-Cyclopropyl-3-[1-(2-hydroxymethyl-3-methyl-3H-imidazol-4-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (53)-   N-Cyclopropyl-4-methyl-3-[1-(5-methyl-[1,3,4]thiadiazol-2-yl)-1H-pyrazol-4-yl]-benzamide    (54)-   N-Cyclopropyl-3-[1-(2,3-dimethyl-3H-imidazol-4-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (55)

Example 16N-Cyclopropyl-3-(1-imidazo[1,2-a]pyridin-3-yl-1H-imidazol-4-yl)-4-methyl-benzamide

A mixture of 3-bromo-imidazo[1,2-a]pyridine-6-carboxylic acid methylester (43 mg, 0.22 mmol), I-39 (0.63 mg, 0.26 mmol), potassium phosphate(0.93 mg, 0.44 mmol), trans-N,N′-dimethyl-cyclohexane-1,2-diamine (0.03mL, 0.18 mmol) in anhydrous DMF (1.0 ml) is degassed with nitrogen. Tothis mixture is added CuI (0.17 mg, 0.09 mmol). The reaction is placedunder nitrogen and the reaction is heated at 100° C. for 24 h. Themixture is then cooled to room temperature, diluted with water andextracted with EtOAc (3×50 mL). The organic layers are combined, washedwith water, then brine, and dried over sodium sulfate. The solution isthen filtered and concentrated under reduced pressure. The resultingresidue is purified by flash silica gel chromatography to provide 0.17mg of the title compound (16).

The following compounds are synthesized in a similar fashion to Example16 using commercially available heteroaryl bromide and/or intermediatesdescribed herein:

-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-imidazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid methyl ester (40)

Example 563-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylicacid

To a suspension of 2 (354 mg, 0.82 mmol) in methanol (15 ml) and water(5 ml) is added lithium hydroxide monohydrate (274 mg, 6.53 mmol). Thereaction gradually turns clear after 2 h and is allowed to stir for 18h. The reaction is then concentrated under reduced pressure. To theresidue is added 2M aq. HCl (3 mL) and the mixture is concentrated toprovide 610 mg of the title compound (56). The residue is used insubsequent steps without further purification.

The following compounds are synthesized in a similar fashion to theprocedure described in Example 56 using intermediates described herein:

-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid (57)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-imidazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid (58)

Example 593-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylicacid (2-hydroxy-ethyl)-amide

To a stirred solution of 56 (178 mg, 56% purity, 0.24 mmol) in DMF (3.7ml) is added Et₃N (0.10 mL, 0.72 mmol), aminoethanol (29 mg, 0.48 mmol),and HATU (136 mg, 0.36 mmol). After 18 h, the reaction is purified byreversed phase HPLC followed by flash silica gel column chromatographyto provide 82 mg of the titled compound (59).

The following compounds are synthesized in a similar fashion to Example59 using commercially available amines:

-   3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid (2-methylamino-ethyl)-amide (60)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-7-carboxylic    acid (2-hydroxy-ethyl)-amide (61)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-7-carboxylic    acid amide (62)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-7-carboxylic    acid (2-methylamino-ethyl)-amide (63)-   N-Cyclopropyl-4-methyl-3-{1-[6-(morpholine-4-carbonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (64)-   N-Cyclopropyl-4-methyl-3-{1-[6-(4-methyl-piperazine-1-carbonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (65)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid dimethylamide (66)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid methylamide (67)-   3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-7-carboxylic    acid methylamide (68)-   3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-carboxylic    acid dimethylamide (69)-   N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(4-methyl-piperazine-1-carbonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (70)

Example 71N-Cyclopropyl-2-fluoro-5-{1-[6-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide

5-(1-{6-[1-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-N-cyclopropyl-2-fluoro-4-methyl-benzamide(71-1) is synthesized according to the Example 2 using intermediateI-30.

To a stirred solution of 71-1 (100 mg, 0.16 mmol) in THF (4 mL) is addedtetrabutylammonium fluoride as a solution in THF (1M, 160 μL, 0.16mmol). The resulting solution is stirred at room temperature for 2.5 h,and then concentrated under reduced pressure. The resulting residue ispurified by flash silica gel chromatography. The isolated material wasfurther purified by preparative reverse phase chromatography to provide66 mg of the title compound (71).

The following compounds are synthesized in a similar fashion as theprocedure described in Example 71 using intermediates described herein.

-   N-Cyclopropyl-3-{1-[6-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide    (72)-   N-Cyclopropyl-3-(1-{6-[hydroxy-(tetrahydro-pyran-4-yl)-methyl]-imidazo[1,2-a]pyridin-3-yl}-1H-pyrazol-4-yl)-4-methyl-benzamide    (73)-   N-Cyclopropyl-3-{1-[6-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-imidazol-4-yl}-4-methyl-benzamide    (74)-   N-Cyclopropyl-2-fluoro-5-{1-[6-(1-hydroxy-1-methyl-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide    (75)

Example 763-[1-(6-Acetyl-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-N-cyclopropyl-4-methyl-benzamide

To a solution of 72 (660 mg, 1.6 mmol) in anhydrous DCM (30 mL) is addedDess-Martin reagent (725 mg, 1.70 mmol). After 30 min, the reaction isdiluted with a saturated aqueous NaHCO₃ solution (5 mL), and stirred for20 min. The mixture is filtered through celite, and the phases areseparated. The organic layer is washed with brine (50 mL), dried overMgSO₄, filtered, and concentrated under reduced pressure. The residue ispurified by flash silica gel column chromatography to provide 618 mg ofthe title compound (76).

Example 77N-Cyclopropyl-4-methyl-3-{1-[6-(oxetane-3-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide

To a stirred solution of 28 (70 mg, 0.16 mmol) in a mixture ofacetonitrile (2.0 mL) and water (1.0 mL) is added ruthenium(III)chloridehydrate (2 mg, 0.01 mmol) and sodium metaperiodate (202 mg, 0.94 mmol).After 1 h, the reaction is diluted with EtOAc (10 mL) and water (5 mL).The layers are separated and the organic layer is extracted with EtOAc(3×), washed with brine (5 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The resulting residue is purifiedby reversed phase HPLC (29-49% ACN in water with NH₄HCO₃) to provide 11mg of the title compound (77).

Example 78N-Cyclopropyl-3-{1-[7-hydroxy-6-(2-methyl-propane-2-sulfonyl)-imidazo[1,2-a]pyridin-2-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide

To a stirred solution of 35 (200 mg, 0.39 mmol) in DMF (5.0 mL) is addedNaSi—Pr (387 mg, 3.94 mmol). The reaction is stirred at 150° C. for 1 h.The reaction is cooled to room temperature and concentrated underreduced pressure. The resulting residue is purified by reversed phasechromatography to provide 35 mg of the title compound (78).

Example 793-{1-[6-(Azetidine-3-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-N-cyclopropyl-4-methyl-benzamide

3-{3-[4-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridine-6-sulfonyl}-azetidine-1-carboxylicacid tert-butyl ester (79-1) is synthesized according to the Example 2using intermediates described herein.

To a stirred solution of 79-1 (15 mg, 0.03 mmol) in MeOH (1.0 mL) isadded a solution of 4M HCl in dioxane (130 μL, 0.52 mmol). The reactionis stirred at room temperature for 18 h, and then concentrated underreduced pressure. The resulting residue is purified by preparativereversed phase HPLC to provide 10 mg of the title compound (79).

The following compound is synthesized in a similar fashion as describedin Example 79 using intermediates described herein.

-   N-Cyclopropyl-4-methyl-3-{1-[6-(piperidine-4-sulfonyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide    (80)

Example 81N-Cyclopropyl-2-fluoro-5-{1-[6-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide

A sample of 50 (250 mg, 0.6 mmol) is separated by chiral hplc (ChiralCelOJ-H 20×250 mm, 22% EtOH:Heptane, 10 ml/min, 38 C). The first peak toelute is assigned as 81-1 (52 mg) and the second peak as 81-2 (56 mg).

Example 82N-Cyclopropyl-3-{1-[6-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide

A sample ofN-Cyclopropyl-3-{1-[6-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide(100 mg, 0.25 mmol) is separated by chiral hplc (ChiralCel OJ-H 20×250mm, 20% EtOH (0.1% DEA):Heptane @ 10 ml/min, 35 C). The first peak toelute is assigned as 82-1 (39 mg) and the second peak as 82-2 (41 mg).

(82-1 and 82-2)

Example 84 N-Cyclopropyl-4-methyl-3-(1‘-methyl-I’H-[1,4′]bipyrazolyl-4-yl)-benzamide

A sample of I-36 (75 mg, 0.31 mmol), 4-bromo-1-methyl-1H-pyrazole (48mg, 0.47 mmol), CuI (24 mg, 0.12 mmol) and potassium phosphate (132 mg,0.62 mmol) are combined in degassed DMF (1.5 mL). To this mixture isadded trans-1,2-Bis(methylamino)cyclohexane (0.04 mL, 0.25 mmol) and thesuspension is heated at 100° C. After 18 h, water (0.15 mL) is addedfollowed by 3 mL of a mixture of 10% water in DMF. The reaction isfiltered and the eluent is purified by reversed phase HPLC to afford 38mg of (84).

The following compounds are synthesized in a similar fashion asdescribed in Example 84 using aryl bromides from commercial sources oras described herein:

-   N-Cyclopropyl-3-{1-[7-(2-methoxy-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide    (85)-   N-Cyclopropyl-3-[1-(7-methoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (86)-   N-Cyclopropyl-4-methyl-3-[1-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-benzamide    (87)-   N-Cyclopropyl-4-methyl-3-[1-(2-pyrazol-1-yl-thiazol-5-yl)-1H-pyrazol-4-yl]-benzamide    (88)-   N-Cyclopropyl-3-[1-(2-hydroxymethyl-thiazol-4-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide    (89)

Example 90N-Cyclopropyl-4-methyl-3-{1-[5-(2-methyl-propane-2-sulfonyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-3-yl]-1H-pyrazol-4-yl}-benzamide

A sample of I-36, I-34 (134 mg, 0.41 mmol), CuI (2 mg, 0.012 mmol) andpotassium phosphate (176 mg, 0.83 mmol) are combined in degassed dioxane(1.4 mL) and DMSO (0.5 mL). Ethylene diamine (0.83 □L, 0.012 mmol) isadded and the suspension is heated at 60° C. After 16 h, additional I-34(134 mg, 0.41 mmol), copper iodide (20 mg, 0.10 mmol) andtrans-1,2-bis(methylamino)cyclohexane (0.05 mL, 0.33 mmol) are added andthe reaction is heated at 120° C. After heating for an additional 16hours, the reaction is diluted with EtOAc (4 mL) and the suspension isfiltered through a short plug of silica gel (12 mm wide×15 mm high) andthe silica plug is eluted with EtOAc (2×2 mL). The combined eluents areconcentrated under reduced pressure and the residue is dissolved in amixture of 10% water in DMSO (2 mL) and purified by reversed phase HPLCto yield 20 mg of the title compound (90).

Example 91N-Cyclopropyl-3-[1-(6-methoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide

A sample of I-36, 3-bromo-6-methoxy-imidazo[1,2-a]pyridine (134 mg, 0.41mmol), copper iodide (24 mg, 0.12 mmol) and potassium phosphate (132 mg,0.62 mmol) are combined in degassed DMF (1.5 mL). To this mixture isadded trans-1,2-Bis(methylamino)cyclohexane (0.04 mL, 0.25 mmol) and thesuspension is heated to 100° C. After 18 h, additional CuI (24 mg, 0.12mmol) and potassium phosphate (66 mg, 0.31 mmol) are added and theheating is continued. After heating an additional 16 hours, the reactionis diluted with EtOAc (1 mL) and the suspension is filtered through ashort plug of silica and the silica plug is eluted with EtOAc (2×2 mL).The combined eluents are concentrated under reduced pressure and theresidue is dissolved in a mixture of 10% water in DMSO (2 mL) andpurified by reversed phase HPLC to yield 26 mg of (91).

Example 92N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(1-oxetan-3-yl-piperidin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide

The amine salt I-41 (400 mg, 0.8 mmol) is dissolved in MeOH (10 mL),then HOAc (97 mg, 1.6 mmol) and the ketone (0.29 mL, 4 mmol) are added.The solution is stirred for 30 minutes. NaBH₃CN is then added (0.5 g,8.1 mmol) and the reaction is stirred overnight at 50° C. After coolingdown to room temperature, the reaction is quenched by the addition ofNaHCO₃, extracted with EtOAc. The combined extracts are concentrated andthe residue is purified by flash chromatography (25 g, 0-5% MeOH/DCM) toafford compound 92 (220 mg, 53%).

Example 93N-Cyclopropyl-5-{1-[6-(1-dimethylcarbamoylmethyl-piperidin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-2-fluoro-4-methyl-benzamide

I-41 (1.3 g, 2.6 mmol) is dissolved in DMF (10 mL). iPr₂NEt (4.8 mL, 260mmol) and the alkyl bromide (520 mg, 3.2 mmol) are added and thesolution is stirred at 50° C. for 2 h. The solvent is removed and theresidue is diluted with EtOAc, washed with NaHCO₃, brine andconcentrated to give a residue, which is purified by flashchromatography (25 g, 0-10% MeOH/DCM), giving crude product contaminatedwith base. This crude is then purified by reverse phase column (60 g,0-60% ACN/H2O), giving product as FO salt. This is salt is redissolvedin DCM, washed with Na2CO3, concentrated and purified by flashchromatography (25 g, 0-10% MeOH/DCM) to afford 93 as free base (810 mg,57%).

Example 94N-Cyclopropyl-2-fluoro-5-{1-[6-(4-fluoro-1-methylpiperidin-4-yl)-7-methoxyimidazo[1,2-a]pyridin-3-yl]-H-pyrazol-4-yl}-4-methyl-benzamide

To a solution of I-24-2 (50.0 g, 220 mmol) in THF (1 L) at −15° C. isadded i-PrMgCl—LiCl (1.3M in THF, 338 mL, 440 mmol) drop-wise over 30min. The mixture is stirred for an additional 30 min and the ketone(92.1 g, 462 mmol) in THF (180 mL) is added drop-wise over 20 min. Theresulting mixture is stirred at rt for 24 h. The mixture is quenchedwith saturated aq. NH₄Cl (400 mL) and concentrated. Water is added (400mL) and extracted with EtOAc (2×600 mL). The combined extracts arewashed with brine (400 mL) and concentrated. The crude residue isdissolved in DCM and purified by silica gel chromatography (1-8% MeOH inDCM) to afford the hydroxy piperidine product (30.7 g, 68.1 mmol) as asolid.

the above hydroxy piperidine product (24.6 g, 70.9 mmol) under argon at0° C. in DCM (470 mL) is added NBS (11.4 g, 63.8 mmol) portion-wise over10 min. The resulting dark green solution was stirred at 0° C. for 45min. The 0° C. mixture is quenched with saturated aq NaHCO₃ (380 mL).Water is then added (190 mL) and the mixture extracted with DCM (2×250mL). The combined organic layers are concentrated and the crude productpurified by silica gel chromatography (0-5% MeOH in DCM) to givetert-butyl-4-{3-bromo-7-methoxyimidazo[1,2-a]pyridine-6-yl}-4-hydroxypiperidine-1-carboxylate(22.5 g, 52.8 mmoL) as a white solid.

In a pressure-flask with 200 mL of degassed DMF (200 mL) is addedtert-butyl-4-{3-bromo-7-methoxyimidazo[1,2-a]pyridine-6-yl}-4-hydroxypiperidine-1-carboxylate(19.9 g, 46.7 mmol) copper iodide (4.4 g, 23.3 mmol),(1S,2S)—N1,N2-dimethyl cyclohexane-1,2-diamine (7.3 mL, 46.7 mmol), I-37(14.5 g, 56.0 mmol) and potassium phosphate (19.8 g, 93.4 mmol). Thereaction mixture is heated at 90° C. for 24 h. The mixture is cooled tort in a water bath and diluted with EtOAc (420 mL). The mixture isfiltered through celite and evaporated. The resulting residue isportioned between DCM and water. The organic layer is dried with MgSO₄and filtered through celite and evaporated. The resulting thick residueis dissolved in MeOH (400 mL) and water (1.4 L) added drop wise. Theresulting solid precipitate was filtered and then purified by silica gelchromatography (100% EtOAc for 10 min, then 0-10% MeOH in EtOAc over 35min) to give4-{3-[4-(5-cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-7-methoxy-piperidine-1-carboxylicacid tert-butyl ester (15 g, 20.8 mmol, 84% pure).

To a solution of4-{3-[4-(5-cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-7-methoxy-piperidine-1-carboxylicacid tert-butyl ester (15 g, 20.8 mmol) in DCM (250 mL) at −78° C. isadded [Bis(2-methoxythyl)amino]sulfur trifuloride (50% in THF, 21.3 mL,49.6 mmol) drop-wise. The mixture is stirred at −78° C. for 10 min. Themixture is allowed to warm to −30° C. over 1 h and then stirred at rtfor 1.5 h. The mixture is cooled to 0° C. and quenched with slowaddition of saturated aq. NaHCO₃ (150 mL). The mixture is stirred for 5min with bubbling occurring. The organic layer is separated and the aqlayer extracted with DCM (2×50 mL). The combined organics are washedwith water (100 mL) and dried with sodium sulfate, filtered andconcentrated. The resulting crude material is purified by silica gelchromatography (0-10% MeOH in DCM) to give4-{3-[4-(5-cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-7-methoxy-imidazo[1,2-a]pyridin-6-yl}-4-fluoro-piperidine-1-carboxylicacid tert-butyl ester (10.4 g, 17.2 mmol) as a solid.

To a solution of4-{3-[4-(5-cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-7-methoxy-imidazo[1,2-a]pyridin-6-yl}-4-fluoro-piperidine-1-carboxylicacid tert-butyl ester (17.8 g, 29.4 mmol) in MeOH (120 mL) is added 4MHCl in dioxane (73.5 mL, 293.9 mmol) and the mixture stirred for 1 h.The mixture is concentrated and the residue dried in a vacuum over at50° C. for 2 h to give crudeN-cyclopropyl-2-fluoro-5-{1-[6-(4-fluoro-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridine-3-yl]-1H-pyrazol-4-yl}-methyl-benzamidehydrochloride (17.6 g, 32.5 mmol) which was used without furtherpurification.

To a solution ofN-cyclopropyl-2-fluoro-5-{1-[6-(4-fluoro-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridine-3-yl]-1H-pyrazol-4-yl}-methyl-benzamidehydrochloride (17.6 g, 32.5 mmol) in DCM (335 mL) is added formaldehyde(9.7 mL, 130.2 mmol) and sodium triacetoxyborohydride (27.6 g, 130.2mmol) and stirred for 45 min. The mixture is quenched with saturated aqNaHCO₃ (350 mL) over 30 min. The layers are separated and the aq layeris extracted with DCM (2×200 mL). The combined organics were washedwater (2×200 mL), dried over Na₂SO₄, filtered and concentrated. Thecrude residue is purified by prep-HPLC to giveN-Cyclopropyl-2-fluoro-5-{1-[6-(4-fluoro-1-methylpiperidin-4-yl)-7-methoxyimidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-4-methyl-benzamide(15.0 g, 28.8 mmol) as a white solid.

Example 95N-Cyclopropyl-5-[1-(6-dimethylaminomethyl-7-methoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-2-fluoro-4-methyl-benzamide

To a solution of 4-Methoxy-pyridin-2-ylamine (45 g; 0.362 mol; 1.0 eq.)in HOAc (1000 mL) is added a solution of Br₂ (57.9 g; 0.362 mol; 1.0eq.) in HOAc (260 mL) dropwise within 0.5 h. A large amount of whitesolid is generated. The resultant mixture is stirred at 18° C. for 1.5h. After filtration, the filter cake is taken up with EtOAc (1500 mL)and washed with sat. NaHCO₃ (500 mL×2), water (300 mL) and brine (200mL), dried over Na₂SO₄, filtered and concentrated to afford5-Bromo-4-methoxy-pyridin-2-ylamine (53.0 g; 0.26 mol) as a white solid,which is used in next step without purification.

To a solution of 5-Bromo-4-methoxy-pyridin-2-ylamine (53 g, 0.261 mol,1.0 eq.) in EtOH:H2O=4:1 (500 mL) is added chloro-acetaldehyde (24.6 g,0.31 mol), then NaHCO₃ (26.3 g, 0.313 mol) is added. The resultantmixture is heated to 90° C. for 4 h. After cooling to r.t., the organicsolvent is evaporated. The residue is extracted with DCM (200 mL×3). Theorganic layers are combined, dried over Na₂SO₄, filtered andconcentrated. The crude product is purified by silica gel chromatography(DCM:MeOH=50:1) to afford compound6-Bromo-7-methoxy-imidazo[1,2-a]pyridine (39 g, 66%) as a brown solid.

To a solution of 6-Bromo-7-methoxy-imidazo[1,2-a]pyridine (34.9 g, 0.154mol, 1.0 eq.) in MeOH (350 ml) and Toluene (350 ml) is added TEA (23 g,0.231 mol, 1.5 eq.), then Pd(dppf)Cl₂ (11.2 g, 0.015 mol, 0.1 eq.) isadded under an N₂ atmosphere. The resultant mixture is heated at 80° C.under a CO atmosphere (3 MPa) for 16 h. The solvent is removed undervacuum. The residue is purified by column chromatography (DCM) andwashed with PE:EA=1:1 (20 mL) to afford7-Methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (20 g,63%) as a brown solid.

To a solution of 7-Methoxy-imidazo[1,2-a]pyridine-6-carboxylic acidmethyl ester (20 g, 97 mmol, 1.0 eq.) in CHCl₃ (400 ml) is added NBS (17g, 97 mmol, 1.0 eq.) at −10° C. under an N₂ atmosphere. The resultantsolution is allowed to warm to 0° C. and stirred for 20 min. Afterdilution with DCM (400 mL), the resultant solution is washed with water(200 mL×2) and brine (300 mL). The organic layer is separated, driedover Na₂SO₄, filtered and concentrated. The residue is washed with amixture solvent PE:EA=1:1 (500 mL) and DCM (100 mL) to afford compound3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester(15.5 g, 54 mmol) as a pale solid.

3-Bromo-7-methoxy-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester(10 g, 35 mmol) is suspended in dry THF (200 mL) and to this is addedLAH (1M, 105 mL, 105 mmol) dropwise via an addition funnel at RT. Thereaction is allowed to stir at RT for 2 h. To the mixture is added water(2 mL), followed by 15% aq NaOH (2 mL) and again water (2 mL). Themixture is stirred for 1 h and the solids removed by filtration. Thesolids are washed with hot methanol/DCM and the filtrate wasconcentrated under reduced pressure to give the crude material which waspurified by silica gel chromatography (2-10% MeOH in DCM) to give(7-methoxyimidazolo[1,2-a]pyridin-6-yl)-methanol (1.7 g, 9.5 mmol).

(7-methoxyimidazolo[1,2-a]pyridin-6-yl)-methanol (2.7 g, 13.8 mmol) isdissolved in MeCN (150 mL) and MeOH (10 mL) with heat and sonication.NIS is then added (4.3 g, 19.3 mmol) and allowed to stir for 30 min.Satd aq. Na₂CO₃ was added and the mixture extracted with EtOAc (3×100mL). The combined organic extracts are washed with satd Na₂CO₃, brineand dried with MgSO₄. The mixture is filtered and concentrated to give(3-iodo-7-methoxyimidazo[1,2-a]pyridine-6-yl)methonal which is usedwithout further purification.

3-iodo-7-methoxyimidazo[1,2-a]pyridine-6-yl)methonal (2.6 g, 8.5 mmol)is dissolved in DMF (25 mL) and to this is added I-37 (2.8 g, 11.1mmol), trans-1,2-bis(methylamino)cyclohexane (1.1 mL, 6.8 mmol), CuI(0.84 g, 4.3 mmol), potassium phosphate tribasic (4.5 g, 21.4 mmol) andthe mixture heated at 75° C. overnight. The reaction is cooled to RT anddiluted with EtOAc and filtered through celite with EtOAc and waterwashing. The organic layer is separate, concentrated and the cruderesidue purified by prep-HPLC to giveN-Cyclopropyl-2-fluoro-5[1-(6-hydroxymethyl-7-methoxy-imidazo[1,2-a]pyridine-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide(1.3 g, 3.0 mmol).

(6-hydroxymethyl-7-methoxy-imidazo[1,2-a]pyridine-3-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide(0.69, 1.6 mmol) was dissolved in DCM (30 mL) and DIPEA (0.414 mL, 2.4mmol) is added and the reaction cooled to 0° C. in an ice bath. Asolution of thionyl chloride (0.14 mL, 1.9 mmol) in DCM (1 mL) is addedand the reaction is allowed to stir overnight. An additional equivalentof thionyl chloride in DCM (1 mL) is added and the mixture stirred for 4h. A subsequent additional equivalent of thionyl chloride in DCM (1 mL)is added and the mixture stirred for 4 h. To the mixture is then addedsatd. Na₂CO₃ and extracted with DCM. The organic layer is separated andconcentrated to give the crude product which is purified by silica gelchromatography (1-5% MeOH in DCM) to give5-[1-(6-Chloromethyl-7-methoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-N-cyclopropyl-2-fluoro-4-methyl-benzamide(0.15 g, 0.33 mmol) as a white solid.

5-[1-(6-Chloromethyl-7-methoxy-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-N-cyclopropyl-2-fluoro-4-methyl-benzamide(0.1 g, 0.24 mmol) is dissolved in DCM and to this is added dimethyamine(2.0M in DCM, 1.7 mL, 3.3 mmol) and the reaction allowed to stir at RTovernight. The mixture is concentrated and purified directly by columnchromatography (25-100% EtOAc in heptanes) to give 95 (0.1 g, 0.24 mmol)as a white solid.

Example 96N-Cyclopropyl-5-{1-[7-ethoxy-6-(4-fluoro-1-methyl-piperidin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-2-fluoro-4-methyl-benzamide

4-Ethoxy-pyridin-2-ylamine (15 g, 109 mmol) is dissolved in HOAc (100mL) and cooled to 0° C. Bromine is added dropwise with vigorousstirring. The mixture is allowed to stir at RT for 30 minutes at whichpoint a precipitate forms. The mixture is stirred for 30 min and thesolids collected by filtration, washed with EtOAc in dried in a vacuumoven to give 5-bromo-4-ethoxy-pyridin-2-ylamine hydrobromide (23.3 g,78.2 mmol).

5-bromo-4-ethoxy-pyridin-2-ylamine hydrobromide (23.4 g, 78.5 mmol) isdissolved in EtOH (500 mL) and to this is added sodium hydrogencarbonate (26.4 g, 314 mmol). 2-chloroacetaldehyde (14.9 mL, 118 mmol)is then added dropwise. After the addition, the mixture is heated at115° C. for 1 h and then cooled to RT and allowed to stir overnight. Themixture is filtered and the filtrate concentrated under reducedpressure. The residue is partitioned between EtOAc and water. Theorganic layer is separated, dried with MgSO₄, filtered and concentratedto give 6-Bromo-7-ethoxy-imidazo[1,2-a]pyridine (6.8 g, 28.2 mmol).

6-Bromo-7-ethoxy-imidazo[1,2-a]pyridine (0.92 g, 3.8 mmol) is dissolvedin THF (40 mL). The solution is cooled to −20° C. and then iPrMgCl LiCLcomplex (1.3M in THF, 5.9 mL, 7.6 mmol) is added dropwise. After 30 min1-Boc-4-piperidone (1.6 g, 8.0 mmol) is added and the reaction allowedto warm to RT. The mixture is quenched with satd NH₄Cl and extractedwith EtOAc. The organics are seperated and dried with MgSO₄, filteredand concentrated to give the crude product which was purified by silicagel chromatography (0-10% MeOH in DCM) to give tert-butyl4-(7-ethoxyimidazo[1,2-a]pyridine-6-yl)-4-hydroxypiperidine-1-carboxylate(0.38 g, 1.0 mmol).

Tert-Butyl4-(7-ethoxyimidazo[1,2-a]pyridine-6-yl)-4-hydroxypiperidine-1-carboxylate(0.38 g, 1.0 mmol) is dissolved in DCM (8 mL) and cooled to 0° C. Tothis is added NBS (0.19 g, 1.1 mmol) and the mixture stirred at RTovernight. The mixture is diluted with DCM and washed with satd NaHCO₃.The organic layer is separated, dried with MgSO₄ and concentrated underreduced pressure to give the crude product which is purified by silicagel chromatography (0-10% MeOH in DCM) to givetert-butyl-4-(3-bromo-7-ethoxyimidazo[1,2-a]pyridine-6-yl)-4-hydroxypiperidine-1-carboxylate(0.39 g, 0.87 mmol).

tert-butyl-4-(3-bromo-7-ethoxyimidazo[1,2-a]pyridine-6-yl)-4-hydroxypiperidine-1-carboxylate(0.39 g, 0.87 mmol) is dissolved in DMF (20 mL) and to this is added CuI(0.066 g, 0.35 mmol), I-37 (0.25 g, 0.95 mmol) potassium phosphatetribasic (0.37 g, 1.7 mmol) and(1S,2S)—N1,N2-dimethylcyclohexane-1,2-diamine (0.11 mL, 0.69 mmol) anddegassed with argon. The reaction vessel is sealed at the mixture heatedat 85° C. overnight. The mixture is cooled to RT and diluted with EtOAc(150 mL). The mixture is filtered through celite and the filtrateevaporated. The residue is partitioned between EtOAc and water. Theorganic layer is separated, dried with MgSO₄ and concentrated to givethe crude product that was purified by silica gel chromatography (0-5%MeOH in DCM) to give tert-butyl4-(3-{4-[5-(cyclopropylcabamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}-7-ethoxyimidazo[1,2-a]pyridine-6-yl)-4-hydroxypiperidine-1-carboxylate(0.36 g, 0.58 mmol).

Tert-Butyl4-(3-{4-[5-(cyclopropylcabamoyl)-4-fluoro-2-methylphenyl]-1H-pyrazol-1-yl}-7-ethoxyimidazo[1,2-a]pyridine-6-yl)-4-hydroxypiperidine-1-carboxylate(0.36 g, 0.58 mmol) is dissolved in DCM (5 mL) and cooled in a dryice/acetone bath. To this added Bis(2-methoxyethyl)amino]sulfurtrifluoride (50% in THF, 0.32 mL, 0.76 mmol) dropwise. The mixture wasstirred in the bath for 30 min and then transferred to a water bath for1 h. The mixture is quenched at 0° C. with NaHCO₃. The mixture isdiluted with DCM and extracted. The organic phase is separated andconcentrated under reduced pressure to give the crude product which ispurified by prep-HPLC to give4-{3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methylphenyl)-pyrazol-1-yl]-7-ethoxy-imidazo[1,2-a]pyridin-6-yl}-4-fluoro-piperidine-1-carboxylicacid tert-butyl ester (0.15 g, 0.25 mmol).

4-{3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methylphenyl)-pyrazol-1-yl]-7-ethoxy-imidazo[1,2-a]pyridin-6-yl}-4-fluoro-piperidine-1-carboxylicacid tert-butyl ester (0.15 g, 0.25 mmol) is dissolved in DCM (5 mL) andMeOH (1 mL) and to this is added HCl in dioxane (4M, 4 mL). The mixtureis stirred at RT for 2 h. The mixture is concentrated under reducedpressure to giveN-Cyclopropyl-5-{1-[7-ethoxy-6-(4-fluoro-piperidin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-1Hpyrazol-4-yl}-2-fluoro-4-methyl-benzamidehyrdrochloride (0.14 g, 0.24 mmol).

N-Cyclopropyl-5-{1-[7-ethoxy-6-(4-fluoro-piperidin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-1Hpyrazol-4-yl}-2-fluoro-4-methyl-benzamidehyrdrochloride (0.14 g, 0.24 mmol) is dissolved in DCM (5 mL) and MeOH(1 mL). To this is added formaldehyde (0.071 mL, 0.98 mmol) and sodiumbis(acetyloxy)boranuidyl acetate (0.21 g, 0.98 mmol). The mixture wasstirred at RT for 15 min and then quenched with NaHCO₃ and extractedwith DCM. The combined organic extracts were dried with MgSO₄, filteredand concentrated under reduced pressure. The residue was triturated withMeOH and filtered to give 96 as a white solid (0.081 g, 0.15 mmol).

Example 97N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-(1-methyl-azetidin-3-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide

6-Bromo-imidazo[1,2-a]pyridine (1.0 g, 0.005 mol) was charged in amicrowave vial and to this is added 4,4′-di-tert-butyl-2,2′-biprydine(0.14 g, 0.001 mol), 3-bromo-azetidine-1-carboxylic acid tert-butylester (1.2 g, 0.005 mol), zinc powder (0.66 g, 0.01 mol), NiI₂ (0.16 g,0.001 mol) and MgCl₂ (0.48, 0.005 mol). To this is added pyridine (0.4g, 0.005 mol) and DMA (15 mL). The reaction was closed and heated at 65°C. for 16 h. The mixture is cooled to RT, diluted with EtOAc and washedwith satd NaHCO₃ and brine. The organic layer is concentrated and theresidue purified by silica gel chromatography (0-100% EtOAc in heptans,followed by 5% MeOH in DCM) to give the crude product which wassubsequently purified by prep-HPLC to give3-imidazo[1,2-a]pyridine-6-yl-azetidine-1-carboxylic acid tert-butylester (0.85 g, 3.1 mmol).

3-Imidazo[1,2-a]pyridine-6-yl-azetidine-1-carboxylic acid tert-butylester (0.85 g, 3.0 mmol) is dissolved in CHCl₃ (15 mL) and to this isadded NBS and the mixture allowed to stir at RT for 2 h. The reaction isconcentrated under reduced pressure and the residue is diluted withEtOAc and washed with satd NaHCO₃, brine and the organic layerconcentrated. The resulting crude product is purified by silica gelchromatography (0-100% EtOAc in heptanes) to give3-(3-bromo-imidazo[1,2-a]pyridine-6-yl)-azetidine-1-carboxylic acidtert-butyl ester (0.84 g, 2.4 mmol).

3-(3-Bromo-imidazo[1,2-a]pyridine-6-yl)-azetidine-1-carboxylic acidtert-butyl ester (0.84 g, 2.4 mmol) is dissolved in DMF (8.0 mL) and tothis is added CuI (0.23 g, 1.2 mmol), (1R,2R)-dimethylaminoacyclohexane(0.27 g, 1.9 mmol), I-37, (0.74 g, 2.9 mmol) and potassium phosphatetribasic (1.0 g, 4.8 mmol) and the mixture heated at 65° C. overnight.The mixture was cooled to RT and diluted with EtOAc. The mixture iswashed with water, brine and the organic layer concentrated to give thecrude product which is purified by silica gel chromatography (0-100%EtOAc in heptanes) followed by reverse phase chromatography (10-100%water/MeCN with 0.5% formic acid) to give3-{3-[4-(5-cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidao[1,2-a]pyridine-6-yl}-azetidine-1-carboxylicacid tert-butyl ester (0.62 g, 1.2 mmol).

3-{3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidao[1,2-a]pyridine-6-yl}-azetidine-1-carboxylicacid tert-butyl ester (0.62 g, 1.2 mmol) is dissolved in DCM (5.0 mL)and MeOH (2.0 mL) and to this is added 4M HCl in dioxane (1.8 mL, 7.0mmol). The mixture was cooled in an ice bath and allowed to stirovernight. The mixture was concentrated, diluted with DCM/MeOH andwashed with satd NaHCO₃. The organic layer was concentrated and theresidue purified by silica gel chromatography (0-10% MeOH in DCM with 1%NH₄OH to give5-[1-(6-azetidin-3-yl-imidazo[1,2-a]pyridine-4-yl)-N-cylcopropyl-2-fluoro-4-methyl-benzamide(0.39 g, 0.91 mmol).

5-[1-(6-Azetidin-3-yl-imidazo[1,2-a]pyridine-4-yl)-N-cylcopropyl-2-fluoro-4-methyl-benzamide(0.07 g) is dissolved in MeOH (2 mL) and to this is added formaldehyde(0.13 mL, 1.6 mmol). The mixture is stirred for 30 min then NaBH₃CN(0.10 g, 1.6 mmol) and acetic acid (0.019 g, 0.33 mmol) are added andthe reaction heated at 50° C. overnight. The mixture is cooled to RT,neutralized with satd NaHCO₃ and the organic layer separated. Theorganics are concentrated and the crude product purified by silica gelchromatography (0-5% MeOH in DCM with 1% NH₄OH to give 97 (0.032 g,0.072 mmol).

Example 98N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-((R)-1-methyl-pyrrolidin-3-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide(99)

6-Bromoimidazo[1,2-a]pyridine (3.9 g, 20 mmol),3-bromo-pyrrolidine-1-carboxylic acid tert-butyl ester (5.0 g, 20 mmol),NiI₂ (0.62 g, 2.0 mmol), 4,4′-di-tert-butyl-2,2′-biprydine (0.54 g, 2.0mmol) and MgCl₂ (0.19 g, 20 mmol) in a pressure flask are dissolved inpyridine and DMA. The mixture is heated at 65° C. for 3 days. Themixture is cooled to RT and diluted with EtOAc. The mixture is washedwith satd NaHCO₃, water and brine. The organic layer is concentrated andthe crude product purified by silica gel chromatography (0-10% MeOH inDCM) to give 3-imidazol[1,2a]pyridine-6-yl-pyrrolidine-1-carboxylic acidtert-butyl ester (2.7 g, 6.1 mmol).

3-Imidazol[1,2a]pyridine-6-yl-pyrrolidine-1-carboxylic acid tert-butylester (2.7 g, 6.1 mmol) is dissolved in CHCl₃ (30 mL) and cooled to 0°C. To this is added NBS (1.1 g, 6.1 mmol) and allowed to stir for 30min. The mixture is concentrated and purified by silica gelchromatography. The enantiomers are then separated by chiral HPLC togive (R)-3-(3-Bromo-imidazo[1,2-a]pyridin-6-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester (0.65 mmol, 1.6 mmol) and(S)-3-(3-Bromo-imidazo[1,2-a]pyridin-6-yl)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.59 g, 1.6 mmol). The stereochemistry is arbitrarilyassigned.

(R)-3-(3-Bromo-imidazo[1,2-a]pyridin-6-yl)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.65 mmol, 1.6 mmol) is dissolved in DMF (5.0 mL) andto this is added CuI (0.15 g, 0.81 mmol), 1R,2R-dimethylaminoacylohexane(0.20 mL, 1.3 mmol), 1-37 (0.5 g, 1.9 mmol) and potassium phosphatetribasic (0.69 g, 3.3 mmol) and the mixture heated at 65° C. overnight.The mixture is cooled to RT, diluted with EtOAc and washed with water(2×50 mL) and brine. The organic layer is concentrated and purified bysilica gel chromatography first with 0-10% MeOH in DCM, then 10-95% MeCNin water with 0.1% formic acid to give(R)-3-{3-[4-(5-Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridin-6-yl}-pyrrolidine-1-carboxylicacid tert-butyl ester (0.62 g, 1.1 mmol).

Cyclopropylcarbamoyl-4-fluoro-2-methyl-phenyl)-pyrazol-1-yl]-imidazo[1,2-a]pyridin-6-yl}-pyrrolidine-1-carboxylicacid tert-butyl ester (0.23 g, 0.42 mmol) is dissolved in MeOH (1 mL)and to this is added 4N HCl in dioxane (0.53 mL, 2.1 mmol) and mixturestirred at RT overnight. The reaction is concentrated to giveN-cyclopropyl-2-fluoro-4-methyl-5-[1-((R)-6-pyrrolidin-3yl-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-benzamidehydrochloride (0.26 g, 0.53 mmol).

N-Cyclopropyl-2-fluoro-4-methyl-5-[1-((R)-6-pyrrolidin-3yl-imidazo[1,2-a]pyridin-3-yl)-1H-pyrazol-4-yl]-benzamidehydrochloride (0.20 g, 0.42 mmol) is dissolved in DCM (4 mL) and to thisis added formaldehyde (0.31 mL, 4.2 mmol) and NaBH(OAc)₃ (1.3 g, 6.4mmol) and allowed to stir overnight. The mixture is quenched with satdNaHCO₃ and extracted with DCM (3×50 mL). The combined organic layers arewashed with water, brine and concentrated under reduced pressure. Thecrude material is purified by silica gel chromatropgraphy (10% MeOH inDCM) to give 98 (0.096 g, 0.21 mmol).

Example 99N-Cyclopropyl-2-fluoro-4-methyl-5-{1-[6-((S)-1-methyl-pyrrolidin-3-yl)-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-benzamide

99 was prepared in an analogous fashion as 98 but from(S)-3-(3-Bromo-imidazo[1,2-a]pyridin-6-yl)-pyrrolidine-1-carboxylic acidtert-butyl ester.

Example 100N-Cyclopropyl-2-fluoro-5-{1-[6-(4-fluoro-1-methyl-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridin-3-yl]-1H-imidazol-4-yl}-4-methyl-benzamide

The title compound was prepared in an analogous fashion as example 94using I-39-2.

Example 101N-Cyclopropyl-5-{1-[6-(1-ethyl-4-fluoro-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridin-3-yl]-1H-pyrazol-4-yl}-2-fluoro-4-methyl-benzamide

N-cyclopropyl-2-fluoro-5-{1-[6-(4-fluoro-piperidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridine-3-yl]-1H-pyrazol-4-yl}-methyl-benzamidehydrochloride (0.060 g, 0.12 mmol) is dissolved in DCM (2.0 mL) and tothis is added acetaldehyde (0.019 mL, 0.36 mmol) and NaBH(OAc)₃ (0.10 g,0.45 mmol) and allowed to stir at RT overnight. The mixture is quenchedwith satd NaHCO₃, and extracted with DCM. The combined organic extractswere washed with brine and concentrated to give the crude product whichwas purified by prep-HPLC to give 101 (0.008 g, 0.016 mmol).

HPLC and MS Data for compounds in Table 1 are shown in Table 3, whichare measured using the methods set forth in the following Table 2.

TABLE 2 HPLC Method Gradient Flow Mobile Mobile Time (mL/ Method Phase APhase B (min) % A % B min.) Column A 0.1% 0.1% 0 95.0 5.0 0.8 BEH FormicFormic 1.0 5.0 95.0 2.5 × 50 mm Acid in Acid in 1.3 5.0 95.0 C18, 1.7 μmWater ACN 1.4 95.0 5.0 particle 1.7 95.0 5.0 diameter

Assessment of Biological Properties

RIPK2 inhibition for compounds in Table 1 are shown in Table 3 andmeasured using the following method:

Materials: White, 384-well optiplates (cat.no. 6007290) were purchasedfrom PerkinElmer. The V9103X ADP-Glo Kinase Assay Custom (includingultra-pure ATP) was purchased from Promega. 8His-RIPK2 FL was preparedin-house. All other materials were of highest grade commerciallyavailable.

Method: In a 384-well plate, test compound diluted in assay buffer (1%DMSO final) is mixed with 8His-RIPK2 FL enzyme (final concentration of 8nM). After 15 minutes of pre-incubation at RT, ATP dissolved in assaybuffer is added (final concentration 5 μM). The mixture is incubated for60 minutes at 37° C. in a humidified incubator. Then, ADP Glo Reagent isadded, followed by a 40 minute incubation at rt. Finally, KinaseDetection Reagent is added and the entire mixture is incubated for 40min at RT. The luminescence signal is measured with an Envision readerto determine the amount of ADP produced. Assay buffer: 25 mM HEPES(4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid), 0.1% BSA (bovineserum albumin), 10 mM MgCl2, 5 mM MnC12, 50 mM KCl, 0.01% CHAPS(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), 10 μMNa3VO4, 1 mM DTT (dithiothreitol), pH 7.5 All plates contain wells withvehicle controls instead of compound (1% DMSO) as reference for the highsignal (100% CTL (100% of control), high signal), and wells withoutenzyme as reference for low signal (0% CTL, low signal). The luminescentsignal generated is proportional to the ADP produced and is correlatedwith enzyme activity. The analysis of the data is performed by thecalculation of the percentage of ADP production in the presence of thetest compound and RIPK2 as compared to the ADP production in thepresence of RIPK2 plus 50 μMGefitinib. (RLU (relative luminescenceunits)(sample)−RLU(low control))*100/(RLU(high value)−RLU(low control))[RLU=relative luminescence units].

TABLE 3 Example m/z rt (mm) RIPK2 IC₅₀ (nM)  1 476.2 0.55 2.6  2 434.40.87 4.7  3 415.3 0.66 66  5 395.1 0.61 3.5  6 396.1 0.69 12  7 419.10.65 0.99  8 410.1 0.65 14  9 427.2 0.76 3  10 516.3 0.82 1.3  11 395.10.85 2.9  12 396.1 0.75 640  13 358.2 0.63 25  14 381.1 0.69 3  15 357.70.55 11  16 357.2 0.54 45  17 381.1 0.62 7.4  19 477.2 0.78 2.2  20477.2 0.83 970  21 473.1 0.76 6.7  22 477.2 0.71 66  23 445.2 0.68 4.5 25 406.3 0.72 150  26 419.1 0.84 55  27 449.2 0.7 12  28 507.2 0.8 150 29 477.7 0.83 1.6  30 479.2 0.73 170  31 401.2 0.59 4.2  32 375.1 0.583.5  33 495.2 0.8 3.8  34 406.2 0.73 4.4  35 507.2 0.72 1.2  36 524.20.76 1.6  37 507.3 0.74 5.2  38 520.3 0.58 26  39 537.2 0.62 4  40 416.40.73 120  41 429.3 0.66 130  42 363.2 0.82 1700  43 324.1 0.71 26  44394.1 0.95 360  45 407.1 0.77 1.2  46 409.2 0.75 110  47 400.1 0.96 110 48 417.1 0.82 55  49 393.2 0.75 390  50 407.2 0.89 1400  53 352.4 0.58710  54 340.3 0.74 140  55 336.3 0.49 260  56 419.1 0.72 16  57 401.10.64 9.5  58 401.1 0.61 320  59 463.3 0.72 2.4  60 476.3 0.57 2.1  61445.3 0.65 4.8  62 401.4 0.66 4.1  63 458.4 0.31 9.3  64 470.2 0.64 19 65 483.2 0.53 10  66 428.2 0.63 7.6  67 414.7 0.64 3.1  68 415.3 0.693.1  69 446.2 0.71 3  70 501.2 0.6 5.5  71 419.2 0.6 2.6  72 401.2 0.564.3  73 471.2 0.57 31  74 402.3 0.56 55  75 433.2 0.67 1.4  76 400.20.68 9.7  77 478.4 0.71 7.2  78 494.2 0.77 500  79 476.2 0.54 3.2  80504.2 0.56 11  81-1 419.2 0.69 2.4  81-2 419.2 0.69 1.9  82-1 401.2 0.576.7  82-2 401.2 0.58 3.2  84 321.2 0.74 23  85 431.6 0.58 3.9  86 387.20.57 4  87 361.2 0.52 190  88 390.1 0.86 17  89 354.1 0.67 2200  90482.2 0.79 11  91 387.2 0.62 6.5  92 515.3 0.46 1.7  93 544.4 0.47 1.5 94 521.3 0.48 1.4  95 462.2 0.45 2.3  96 535.4 0.50 1.1  97 445.2 0.473.2  98 459.3 0.48 1.4  99 459.3 0.49 1.6 100 521.3 0.44 2.4 101 534.30.48 1.3

Additional assays such as human whole blood TNF inhibition, humanhepatocyte stability and CACO-2 permeability were carried out to obtaincellular potency, stability and cell permeability respectively.

Method of Use

The compounds of the invention are effective inhibitors of RIPK2.Therefore, in one embodiment of the invention, there is provided methodsof treating RIPK2 mediated disorders using compounds of the invention.In another embodiment, there is provided methods of treatingcardiovascular, inflammatory, allergic, pulmonary and fibrotic diseases,renal diseases and cancer using compounds of the invention.

Without wishing to be bound by theory, pharmacological inhibition ofRIPK2 will attenuate pro-inflammatory signaling through the bacterialsensing pathways initiated by NOD1 and NOD2 stimulation. This reductionin inflammatory signaling will provide therapeutic benefit in a varietyof autoinflammatory diseases.

These include:

Cardiovascular diseases including atherosclerosis, myocardialinfarction, stroke, aortic aneurysm, sickle cell crisis,ischemia-reperfusion injury, pulmonary arterial hypertension and sepsis;

Allergic diseases including asthma, allergic rhinitis, rhinosinusitis,atopic dermatitis and urticaria;

Fibrotic diseases including airway remodeling in asthma, idiopathicpulmonary fibrosis, scleroderma, asbestosis;

Pulmonary syndromes including adult respiratory distress syndrome, viralbronchiolitis, obstructive sleep apnea, chronic obstructive pulmonarydisease, cystic fibrosis, and bronchopulmonary dysplasia;

Inflammatory diseases including rheumatoid arthritis, osteoarthritis,gout, glomerulonephritis, interstitial cystitis, psoriasis, inflammatorybowel disease (ulcerative colitis and Crohn's disease), Blau syndrome,systemic lupus erythematosus, transplant rejection, multiple sclerosis,inflammatory pain, inflammatory and allergic ocular diseases;

Autoimmune disease or allergic disorder is selected from rheumatoidarthritis, psoriasis, systemic lupus erythromatosis, lupus nephritis,scleroderma, asthma, Chronic Obstructive Pulmonary Disease (COPD),allergic rhinitis, allergic eczema, multiple sclerosis, juvenilerheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes,inflammatory bowel disease, graft versus host disease, psoriaticarthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease,ulcerative colitis, uveitis and non-radiographic spondyloarthropathy.

Cancer including solid tumors, leukemias and lymphomas; and

Renal diseases such as glomerulonephritis or diabetic nephropathy ordiabetic kidney disease.

Liver disease such as Non-alcoholic fatty liver disease or non-alcoholicsteato-hepatitis (NASH) or cirrhosis of the liver.

For treatment of the above-described diseases and conditions, atherapeutically effective dose will generally be in the range from about0.01 mg to about 100 mg/kg of body weight per dosage of a compound ofthe invention; preferably, from about 0.1 mg to about 20 mg/kg of bodyweight per dosage. For example, for administration to a 70 kg person,the dosage range would be from about 0.7 mg to about 7000 mg per dosageof a compound of the invention, preferably from about 7.0 mg to about1400 mg per dosage. Some degree of routine dose optimization may berequired to determine an optimal dosing level and pattern. The activeingredient may be administered from 1 to 6 times a day.

General Administration and Pharmaceutical Compositions

When used as pharmaceuticals, the compounds of the invention aretypically administered in the form of a pharmaceutical composition. Suchcompositions can be prepared using procedures well known in thepharmaceutical art and comprise at least one compound of the invention.The compounds of the invention may also be administered alone or incombination with adjuvants that enhance stability of the compounds ofthe invention, facilitate administration of pharmaceutical compositionscontaining them in certain embodiments, provide increased dissolution ordispersion, increased antagonist activity, provide adjunct therapy, andthe like. The compounds according to the invention may be used on theirown or in conjunction with other active substances according to theinvention, optionally also in conjunction with other pharmacologicallyactive substances. In general, the compounds of this invention areadministered in a therapeutically or pharmaceutically effective amount,but may be administered in lower amounts for diagnostic or otherpurposes.

Administration of the compounds of the invention, in pure form or in anappropriate pharmaceutical composition, can be carried out using any ofthe accepted modes of administration of pharmaceutical compositions.Thus, administration can be, for example, orally, buccally (e.g.,sublingually), nasally, parenterally, topically, transdermally,vaginally, or rectally, in the form of solid, semi-solid, lyophilizedpowder, or liquid dosage forms, such as, for example, tablets,suppositories, pills, soft elastic and hard gelatin capsules, powders,solutions, suspensions, or aerosols, or the like, preferably in unitdosage forms suitable for simple administration of precise dosages. Thepharmaceutical compositions will generally include a conventionalpharmaceutical carrier or excipient and a compound of the invention asthe/an active agent, and, in addition, may include other medicinalagents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles,or combinations thereof. Such pharmaceutically acceptable excipients,carriers, or additives as well as methods of making pharmaceuticalcompositions for various modes or administration are well-known to thoseof skill in the art. The state of the art is evidenced, e.g., byRemington: The Science and Practice of Pharmacy, 20th Edition, A.Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook ofPharmaceutical Additives, Michael & Irene Ash (eds.), Gower, 1995;Handbook of Pharmaceutical Excipients, A. H. Kibbe (ed.), AmericanPharmaceutical Ass'n, 2000; H. C. Ansel and N. G. Popovish,Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th ed., Lea andFebiger, 1990; each of which is incorporated herein by reference intheir entireties to better describe the state of the art.

As one of skill in the art would expect, the forms of the compounds ofthe invention utilized in a particular pharmaceutical formulation willbe selected (e.g., salts) that possess suitable physical characteristics(e.g., water solubility) that are required for the formulation to beefficacious.

The invention claimed is:
 1. A compound of Formula (I):

or pharmaceutically acceptable salts thereof, wherein: X is N and Y isCH; or X is CH and Y is N; HET is a 5-membered heteroaryl ringcontaining one to three heteroatoms selected from nitrogen and sulfur,wherein each heteroaryl ring is optionally substituted with one or twosubstituents groups independently selected from R³ and R⁴; or HET is a5-membered heteroaryl ring containing one to three heteroatoms selectedfrom nitrogen and sulfur, wherein each heteroaryl ring is substitutedwith two substituents groups selected from R^(a) and R^(b), whereinR^(a) and R^(b) together with the atoms to which they are attached forma 5-6 membered heterocyclic or heteroaryl ring which may be optionallysubstituted with one or two substituents selected from R³ and R⁴; R¹ ishydrogen or F; R² is C₁₋₃ alkyl or Cl; R³ and R⁴ are each independentlyselected from: (a) —H, (b) —O R⁵, (c) —O— C₁₋₆alkyl-O— C₁₋₃ alkyl (d)—O—C₃₋₆ cycloalkyl, (e) —C(O)R⁵, (f) C₁₋₆alkyl optionally substitutedwith one to three —OH, fluoro, heterocyclyl optionally substituted withoxo, C₃₋₆ cycloalkyl, —CO₂R⁵, —O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or—C(O)N(R⁵)(R⁶), (g) C₃₋₆ cycloalkyl optionally substituted with one tothree —OH, one to three fluoro, C₁₋₆alkyl, —OC₁₋₆alkyl,C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl, —CO₂H,—CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl,N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h) —CO₂R⁵, (i) —C(O)N(R⁵)(R⁶), (j)—S(O)₂N(R⁵)(R⁶), (k) —S(O)_(n)-R⁵, (l) a 5-6 membered heteroaryl groupoptionally substituted with one to three groups selected from C₁₋₆alkyl,C₃₋₆cycloalkyl, halogen, —CF₃, —OH, —(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶),—N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃ alkyl,C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN, oxo, phenyl optionally substituted withhalogen and —S(O)_(n)C₁₋₆alkyl, (m) 4-10 membered monocyclic, bicyclicor spirocyclic heterocyclyl group containing nitrogen, sulfur, oroxygen, wherein each heterocyclyl is optionally substituted with with1-3 substituents selected from 3-6 membered monocyclic heterocyclylgroup, halogen, —C₁₋₃alkyl, —C₁₋₃alkyl —O— C₁₋₃alkyl and —C₁₋₃alkyl-C(O)N(R⁵)(R⁶), (n) aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶ are eachindependently selected from —H, 4-6 membered heterocyclyl, —C(O)—C₁₋₃alkyl—C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl, wherein each R⁵ and R⁶ isindependently and optionally substituted with —OH, C₃₋₆ cycloalkyl,—C₁₋₃alkyl, —O— C₁₋₃alkyl, —NH—C₁₋₃ alkyl or —N—(C₁₋₃-alkyl)₂; or R⁵ andR⁶ together with the nitrogen atom to which they are attached form a 4-6membered heterocyclic ring optionally substituted with methyl; and n is0, 1 or
 2. 2. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein: X is N and Y is CH.
 3. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein: X is CH and Y isN.
 4. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein: HET is a 5-membered heteroaryl ring selected frompyrazolyl and imidazolyl, wherein each heteroaryl ring is substitutedwith two substituents groups selected from R^(a) and R^(b); whereinR^(a) and R^(b) together with the atoms to which they are attached forma 5-6 membered heteroaryl ring such that HET is a bicyclic heteroarylring selected from imidazopyridine and pyrazolopyridine which may beoptionally substituted one or two substituents selected from R³ and R⁴.5. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein: HET is pyrazolyl optionally substituted with one ortwo substituents groups selected from R³ and R⁴.
 6. The compound ofclaim 1, or a pharmaceutically acceptable salt thereof, wherein: HET is:

optionally substituted one or two substituents selected from R³ and R⁴.7. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein: HET is:

optionally substituted one or two substituents selected from R³ and R⁴.8. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein: HET is selected from:

optionally substituted one or two substituents selected from R³ and R⁴.9. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein: Het is a 5-membered heteroaryl ring selected frompyrazolyl, imidazolyl, thiazolyl and thiadiazolyl, wherein eachheteroaryl ring is optionally substituted with one or two substituentsgroups independently selected from R³ and R⁴; or Het is a 5-memberedheteroaryl ring selected from pyrazolyl and imidazolyl, wherein eachheteroaryl ring is substituted with two substituents groups selectedfrom R^(a) and R^(b), wherein R^(a) and R^(b) together with the atoms towhich they are attached form a 5-6 membered heterocyclic or heteroarylring which may be optionally substituted with one or two substituentsselected from R³ and R⁴; R³ and R⁴ are each independently selected from:(a) —H, (b) —O R⁵, (c) —O— C₁₋₆alkyl-O—C₁₋₃ alkyl (d) —O—C₃₋₆cycloalkyl, (e) —C(O)R⁵, (f) C₁₋₆alkyl optionally substituted with oneto three —OH, fluoro, heterocyclyl optionally substituted with oxo, C₃₋₆cycloalkyl, —CO₂R⁵, —O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶),(g) C₃₋₆ cycloalkyl optionally substituted with one to three —OH, one tothree fluoro, C₁₋₆alkyl, —OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl,C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl, —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6membered heteroaryl, C₃₋₆heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h)—CO₂R⁵, (i) —C(O)N(R⁵)(R⁶), (j) —S(O)₂N(R⁵)(R⁶), (k) —S(O)_(n)-R⁵ (l) a5-6 membered heteroaryl group optionally substituted with one to threegroups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, —CF₃, —OH,—(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl,C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃alkyl, C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN, oxo,phenyl optionally substituted with halogen and —S(O)_(n)C₁₋₆alkyl, (m)4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl groupcontaining nitrogen, sulfur, or oxygen, wherein each heterocyclyl isoptionally substituted with 1-3 substituents selected from 3-6 memberedmonocyclic heterocyclyl group, halogen, C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶). (n) aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶ are eachindependently selected from —H, 4-6 membered heterocyclyl, —C(O)—C₁₋₃alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl optionally substitutedwith —OH, C₃₋₆cycloalkyl, —NH—C₁₋₃ alkyl or —N—(C₁₋₃-alkyl)₂; or R⁵ andR⁶ together with the nitrogen atom to which they are attached form a 5-6membered heterocyclic ring optionally substituted with methyl; and n is0 or
 2. 10. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein: HET is a 5-membered heteroaryl ring selected frompyrazolyl, imidazolyl, thiazolyl and thiadiazolyl, wherein eachheteroaryl ring is optionally substituted with one or two substituentsgroups independently selected from R³ and R⁴; R³ and R⁴ are eachindependently selected from: (a) —H, (b) —O R⁵, (c) —O— C₁₋₆alkyl-O—C₁₋₃alkyl (d) —O—C₃₋₆ cycloalkyl, (e) —C(O)R⁵, (f) C₁₋₆alkyl optionallysubstituted with one to three —OH, fluoro, heterocyclyl optionallysubstituted with oxo, C₃₋₆ cycloalkyl, —CO₂R⁵, —O— C₁₋₆alkyl, aryl,—N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (g) C₃₋₆ cycloalkyl optionallysubstituted with one to three —OH, one to three fluoro, C₁₋₆alkyl,—OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl,—CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h) —CO₂R⁵, (i)—C(O)N(R⁵)(R⁶), (j) —S(O)₂N(R⁵)(R⁶), (k) —S(O)_(n)-R⁵ (l) a 5-6 memberedheteroaryl group optionally substituted with one to three groupsselected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, —CF₃, —OH,—(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl,C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃alkyl, C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN, oxo,phenyl optionally substituted with halogen and —S(O)_(n)C₁₋₆alkyl, (m)4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl groupcontaining nitrogen, sulfur, or oxygen, wherein each heterocyclyl isoptionally substituted with 1-3 substituents selected from 3-6 memberedmonocyclic heterocyclyl group, halogen, C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶), (n) aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶ are eachindependently selected from —H, 4-6 membered heterocyclyl, —C(O)—C₁₋₃alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl optionally substitutedwith —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or —N—(C₁₋₃-alkyl)₂; or R⁵ andR⁶ together with the nitrogen atom to which they are attached form a 5-6membered heterocyclic ring optionally substituted with methyl; and n is0 or
 2. 11. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein: HET is a 5-membered heteroaryl ring selected frompyrazolyl and imidazolyl, wherein each heteroaryl ring is substitutedwith two substituents groups selected from R^(a) and R^(b); whereinR^(a) and R^(b) together with the atoms to which they are attached forma 5-6 membered heterocyclic or heteroaryl ring which may be optionallysubstituted with one or two substituents selected from R³ and R⁴; R³ andR⁴ are each independently selected from: (a) —H, (b) —O R⁵, (c) —O—C₁₋₆alkyl-O— C₁₋₃alkyl (d) —O—C₃₋₆ cycloalkyl, (e) —C(O)R⁵, (f)C₁₋₆alkyl optionally substituted with one to three —OH, fluoro,heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, —CO₂R⁵,—O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (g) C₃₋₆ cycloalkyloptionally substituted with one to three —OH, one to three fluoro,C₁₋₆alkyl, —OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃,—OC₃₋₆cycloalkyl, —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h) —CO₂R⁵,(i) —C(O)N(R⁵)(R⁶), (j) —S(O)₂N(R⁵)(R⁶), (k) —S(O)_(n)—R⁵ (l) a 5-6membered heteroaryl group optionally substituted with one to threegroups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, —CF₃, —OH,—(CH₂)_(n)CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl,C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃alkyl, C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN, oxo,phenyl optionally substituted with halogen and —S(O)_(n)C₁₋₆alkyl, (m)4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl groupcontaining nitrogen, sulfur, or oxygen, wherein each heterocyclyl isoptionally substituted with 1-3 substituents selected from 3-6 memberedmonocyclic heterocyclyl group, halogen, C₁₋₃alkyl, and C₁₋₃alkyl-C(O)N(R⁵)(R⁶), (n) aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶ are eachindependently selected from —H, 4-6 membered heterocyclyl, —C(O)—C₁₋₃alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl optionally substitutedwith —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or —N—(C₁₋₃-alkyl)₂; or R⁵ andR⁶ together with the nitrogen atom to which they are attached form a 6membered heterocyclic ring optionally substituted with methyl; and n is0 or
 2. 12. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein: X is N and Y is CH; R¹ is F; R² is CH₃ or Cl; HETis imidazopyridinyl which may be optionally substituted with one or twosubstituents selected from R³ and R⁴; R³ and R⁴ are each independentlyselected from: (a) —H, (b) —O R⁵, (c) —O— C₁₋₆alkyl-O— C₁₋₃ alkyl (d)—O—C₃₋₆ cycloalkyl, (e) —C(O)R⁵, (f) C₁₋₆alkyl optionally substitutedwith one to three —OH, fluoro, heterocyclyl optionally substituted withoxo, C₃₋₆ cycloalkyl, —CO₂R⁵, —O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or—C(O)N(R⁵)(R⁶), (g) C₃₋₆ cycloalkyl optionally substituted with one tothree —OH, one to three fluoro, C₁₋₆alkyl, —OC₁₋₆alkyl,C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃, —OC₃₋₆cycloalkyl, —CO₂H,—CO₂R⁵, C₃₋₆cycloalkyl, 5-6 membered heteroaryl, C₃₋₆ heterocyclyl,N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h) —CO₂R⁵, (i) —C(O)N(R⁵)(R⁶), (j)—S(O)₂N(R⁵)(R⁶), (k) —S(O)₂-R⁵ (l) a 5-6 membered heteroaryl groupoptionally substituted with one to three groups selected from C₁₋₆alkyl,C₃₋₆cycloalkyl, halogen, —CF₃, —OH, —(CH₂) CO₂R⁵, —C(O)N(R⁵)(R⁶),—N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃alkyl,C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN, oxo, phenyl optionally substituted withhalogen and —S(O)₂C₁₋₆alkyl, (m) 6 membered monocyclic heterocyclylgroup containing nitrogen wherein the heterocycle is optionallysubstituted with 1-3 substituents selected from 3-6 membered monocyclicheterocyclyl group halogen, C₁₋₃alkyl, and C₁₋₃alkyl- C(O)N(R⁵)(R⁶). (n)aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶are each independently selected from—H, 4-6 membered heterocyclyl, —C(O)—C₁₋₃alkyl —C(O)—C₁₋₃cycloalkyl and—(C₁-C₆)alkyl optionally substituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃alkyl or —N—(C₁₋₃-alkyl)₂; or R⁵ and R⁶ together with the nitrogen atomto which they are attached form a 6 membered heterocyclic ringoptionally substituted with methyl.
 13. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein: X is N and Y is CH;R¹ is F; R² is CH₃ or Cl; HET is imidazopyridinyl or pyrazolopyridinylwhich may be optionally substituted one or two substituents selectedfrom R³ and R⁴; R³ and R⁴ are each independently selected from: (a) —H,(b) —O R⁵, (c) —O— C₁₋₆alkyl-O— C₁₋₃ alkyl (d) —O—C₃₋₆ cycloalkyl, (e)—C(O)R⁵, (f) C₁₋₆alkyl optionally substituted with one to three —OH,fluoro, heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl,—CO₂R⁵, —O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (g) C₃₋₆cycloalkyl optionally substituted with one to three —OH, one to threefluoro, C₁₋₆alkyl, —OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃,—O C₃₋₆cycloalkyl, —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6memberedheteroaryl, C₃₋₆heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h) —CO₂R⁵,(i) —C(O)N(R⁵)(R⁶), (j) —S(O)₂N(R⁵)(R⁶), (k) —S(O)₂-R⁵ (l) a 5-6membered heteroaryl group optionally substituted with one to threegroups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, —CF₃, —OH,—(CH₂) CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl,C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃ alkyl, C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN,oxo, phenyl optionally substituted with halogen and —S(O)₂C₁₋₆alkyl, (m)4-10 membered monocyclic, bicyclic or spirocyclic heterocyclyl groupcontaining nitrogen, sulfur, or oxygen, wherein each heterocyclyl isoptionally substituted with 1-3 substituents selected from 3-6 memberedmonocyclic heterocyclyl group, halogen, C₁₋₃alkyl, or C₁₋₃alkyl-C(O)N(R⁵)(R⁶), (n) aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶ are eachindependently selected from —H, 4-6 membered heterocyclyl, —C(O)—C₁₋₃alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl optionally substitutedwith —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or —N—(C₁₋₃-alkyl)₂; or R⁵ andR⁶ together with the nitrogen atom to which they are attached form a 6membered heterocyclic ring optionally substituted with methyl.
 14. Thecompound of claim 13 or a pharmaceutically acceptable salt thereof,wherein: HET is:

optionally substituted one or two substituents selected from R³ and R⁴;R³ and R⁴ are each independently selected from: (a) —H, (b) —O R⁵, (c)—O— C₁₋₆alkyl-O—C₁₋₃ alkyl (d) —O—C₃₋₆ cycloalkyl, (e) —C(O)R⁵, (f)C₁₋₆alkyl optionally substituted with one to three —OH, fluoro,heterocyclyl optionally substituted with oxo, C₃₋₆ cycloalkyl, —CO₂R⁵,—O— C₁₋₆alkyl, aryl, —N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (g) C₃₋₆ cycloalkyloptionally substituted with one to three —OH, one to three fluoro,C₁₋₆alkyl, —OC₁₋₆alkyl, C₁₋₆alkyl-OC₁₋₆alkyl, C₁₋₆alkyl-OH, CF₃,—OC₃₋₆cycloalkyl, —CO₂H, —CO₂R⁵, C₃₋₆cycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ heterocyclyl, N(R⁵)(R⁶), or —C(O)N(R⁵)(R⁶), (h) —CO₂R⁵,(i) —C(O)N(R⁵)(R⁶), (j) —S(O)₂N(R⁵)(R⁶), (k) —S(O)₂—R⁵ (l) a 5-6membered heteroaryl group optionally substituted with one to threegroups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, halogen, —CF₃, —OH,—(CH₂) CO₂R⁵, —C(O)N(R⁵)(R⁶), —N(R⁵)(R⁶), —NH—S(O)₂C₁₋₆alkyl,C₁₋₆alkoxy, C₁₋₆alkyl-O— C₁₋₃alkyl, C₁₋₆alkylhydroxy, C₁₋₃alkyl-CN, oxo,phenyl optionally substituted with halogen and —S(O)₂C₁₋₆alkyl, (m) 4-10membered monocyclic, bicyclic or spirocyclic heterocyclyl groupcontaining nitrogen, sulfur, or oxygen, wherein each heterocyclyl isoptionally substituted with 1-3 substituents selected from 3-6 memberedmonocyclic heterocyclyl group, halogen, C₁₋₃alkyl, andC₁₋₃alkyl-C(O)N(R⁵)(R⁶), (n) aryl, and (o) —N(R⁵)(R⁶); R⁵ and R⁶ areeach independently selected from —H, 4-6 membered heterocyclyl,—C(O)—C₁₋₃ alkyl —C(O)—C₁₋₃ cycloalkyl and —(C₁-C₆)alkyl optionallysubstituted with —OH, C₃₋₆ cycloalkyl, —NH—C₁₋₃ alkyl or—N—(C₁₋₃-alkyl)₂; or R⁵ and R⁶ together with the nitrogen atom to whichthey are attached form a 6 membered heterocyclic ring optionallysubstituted with methyl.
 15. The compound of claim 13, or apharmaceutically acceptable salt thereof, wherein: HET is:

optionally substituted one or two substituents selected from R³ and R⁴.16. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein: X is N and Y is CH; R¹ is F; R² is CH₃; HET isselected from:


17. A pharmaceutical composition comprising a compound of claim 1, or apharmaceutically acceptable salt thereof, and at least onepharmaceutically acceptable carrier.
 18. A method for modulatingreceptor interacting serine/threonine-protein kinase 2 activity in apatient comprising administering to said patient a therapeuticallyeffective amount of a compound of claim 1, or a pharmaceuticallyacceptable salt thereof.
 19. The method of claim 18, wherein the patienthas an autoimmune disease or allergic disorder.
 20. The method of claim19, wherein the autoimmune disease or allergic disorder is selected fromthe group consisting of: rheumatoid arthritis, psoriasis, systemic lupuserythromatosis, lupus nephritis, scleroderma, asthma, chronicobstructive pulmonary disease, allergic rhinitis, allergic eczema,multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathicarthritis, type I diabetes, inflammatory bowel disease, graft versushost disease, psoriatic arthritis, reactive arthritis, ankylosingspondylitis, Crohn's disease, ulcerative colitis, uveitis andnon-radiographic spondyloarthropathy.
 21. A compound selected from thegroup consisting of:

or the pharmaceutically acceptable salts thereof.
 22. A pharmaceuticalcomposition comprising a compound of claim 21 or a pharmaceuticallyacceptable salt thereof, and at least one pharmaceutically acceptablecarrier.
 23. A compound of formula:

or a pharmaceutically acceptable salt thereof.
 24. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 25. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 26. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 27. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 28. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 29. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 30. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 31. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 32. A compound offormula:

or a pharmaceutically acceptable salt thereof.
 33. A compound offormula:


34. A pharmaceutical composition comprising a compound of claim 33 andat least one pharmaceutically acceptable carrier.
 35. A compound offormula:


36. A pharmaceutical composition comprising a compound of claim 35 andat least one pharmaceutically acceptable carrier.
 37. A compound offormula:


38. A pharmaceutical composition comprising a compound of claim 37 andat least one pharmaceutically acceptable carrier.
 39. A compound offormula:


40. A pharmaceutical composition comprising a compound of claim 39 andat least one pharmaceutically acceptable carrier.
 41. A compound offormula:


42. A pharmaceutical composition comprising a compound of claim 41 andat least one pharmaceutically acceptable carrier.
 43. A compound offormula:


44. A pharmaceutical composition comprising a compound of claim 43 andat least one pharmaceutically acceptable carrier.
 45. A compound offormula:


46. A pharmaceutical composition comprising a compound of claim 45 andat least one pharmaceutically acceptable carrier.
 47. A compound offormula:


48. A pharmaceutical composition comprising a compound of claim 47 andat least one pharmaceutically acceptable carrier.
 49. A compound offormula:


50. A pharmaceutical composition comprising a compound of claim 49 andat least one pharmaceutically acceptable carrier.
 51. A compound offormula:


52. A pharmaceutical composition comprising a compound of claim 51 andat least one pharmaceutically acceptable carrier.